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The Hedgehog (Hh) signaling is an important embryonic developmental pathway
normally responsible for tissue growth, differentiation and patterning. However, aberrant
activity of this signaling cascade has been implicated in several types of cancer.
Therefore, inhibition of the dysregulated pathway is a promising therapeutic target for
treating Hh-dependent malignancies such as basal cell carcinoma (BCC) and
medulloblastoma (MB). Previous studies resulted in the FDA approval of Vismodegib, a
small molecule inhibitor of the Hh pathway, for the treatment of advanced BCC.
Similarly, several other small molecule Hh antagonists have progressed into clinical
trials. Moreover, several components within the Hh pathway have proven to be
druggable in ‘proof-of-concept’ studies. Nonetheless, several challenges in the discovery
and development process for small molecules targeting this pathway have been noted.
For instance, multiple mechanisms of resistance to Hh inhibitors have been identified.
This has prompted extensive search for novel inhibitors that function via mechanisms
that will retain activity in the presence of pathway signaling resistant to current therapy.
Consequently, a ligand based approach was undertaken to develop Hh inhibitors based
on two distinct lead structures namely Vitamin D3 (VD3) and Itraconazole (ITZ). An
interdisciplinary approach utilizing synthetic organic chemistry transformations and
molecular biology techniques was adopted to study the Hh inhibitory effects of probing
relevant biological systems with aforementioned small molecule modulators and their
derivatives. Information thus obtained guided the design of improved second-generation
Hh inhibitors. A structure-activity-relationship study to identify the Hh inhibitory
pharmacophore of VD3 was pursued. Based on the findings, VD3 based anti-Hh

Upasana Banerjee – University of Connecticut, [2014]
analogues with improved potency and selectivity were designed, synthesized and
evaluated. Next, a synthetic methodology for preparing ITZ derivatives with
stereochemically defined hydroxylated side chains was optimized. Preliminary evaluation
of resultant hybrid ITZ analogues obtained via this synthetic route identified Hh inhibitors
demonstrating nanomolar potencies. Taken together, the preliminary identification of
several improved Hh inhibitory scaffolds through these studies will facilitate further
comprehensive biological evaluation of the promising derivatives.
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CHAPTER I: Recent Advances in the Design of Hedgehog Pathway Inhibitors for
the Treatment of Malignancies

1

1. Introduction
The Hedgehog (Hh) signaling pathway is a developmental pathway that plays an
essential role in tissue growth and differentiation during embryogenesis. The Hh
pathway has been implicated in the proper patterning of a variety of human tissues,
including, bone and cartilage, hair follicles, heart and lung muscle, and the central and
peripheral nervous system 1. Hh signaling is significantly less active in adult tissues,
where its primary role appears to be the maintenance of stem cell populations in skin
and the central nervous system. Aberrant regulation of pathway signaling causes
constitutive activation, resulting in uncontrolled cellular proliferation and tumor growth;
most notably in basal cell carcinoma (BCC) and medulloblastoma (MB).
Hh signaling is primarily controlled by two membrane-bound receptors: Patched
(Ptch), a 12 transmembrane domain (TM) cell surface receptor; Smoothened (Smo), a 7
TM G-protein coupled receptor (GPCR)-like receptor; and the glioma-associated
oncogene (Gli) family of zinc-finger transcription factors, which act in a concerted fashion
to regulate pathway activity (Figure 1). In the absence of an Hh ligand [Sonic Hh (Shh),
Indian Hh (IHh), and Desert Hh (DHh)], Ptch represses the activity of Smo through a
complicated mechanism that is not completely understood. In this state, Gli and
Suppressor of Fused (Sufu) form a heteroprotein complex in the cytosol. Sufu serves as
a negative regulator of Gli by promoting phosphorylation of the Gli proteins, ultimately
leading to their ubiquitin/proteasome-mediated proteolysis and the generation of Nterminal truncated forms (Gli R ) that serve as transcriptional repressors of Hh target
genes. On binding of an Hh ligand, Ptch is internalized and its inhibition of Smo is
alleviated. Smo is phosphorylated at its intracellular C-terminus and translocates to the
cell surface membrane of non-motile cilia. The activation and translocation of Smo
disrupts the Sufu-Gli complex, leading to the production of intact, active forms of Gli

2

(GliA). GliA acts a transcriptional activator in the nucleus to stimulate production of the
ubiquitous Hh target genes Gli1, Ptch1, and HHIP (Hh interacting protein). Within the
context of Hh signaling, GliA primarily consists of Gli2 and/or Gli3, while Gli1 is the
predominant Hh-responsive activator that mediates the downstream effects of pathway
activation.

Figure 1. General scheme for the Hh signaling cascade.2 Gli: Glioma-asociated oncogene;
Hh: Hedgehog; Ptch: Patched; Smo: Smoothened; Sufu: Suppressor of Fused.

2. Hh Signaling Pathway and Cancer
2.1 Cellular Mechanisms of Dysregulation
Aberrant regulation of pathway signaling results in its constitutive activation,
which can ultimately drive uncontrolled cellular proliferation and tumor growth. While
multiple mechanisms through which dysregulated or hyperactive Hh signaling
contributes to tumor formation, growth, and metastasis have been identified, the best
characterized are Hh ligand independent. These forms of Hh -dependent cancer are
characterized by mutations in key pathway signal transducers, i.e. Ptch and Smo. Basal
cell carcinoma (BCC) is the most common human cancer, accounting for ~80% of
nonmelanoma skin cancers and affecting approximately 10 million people worldwide on
an annual basis

3, 4

. Genetic analyses have demonstrated that a majority of sporadic

BCCs exhibit detectable genetic mutations in Ptch1 (~75%), Smo (10%), or Sufu (~5%)
3

5, 6

. Mutations in Ptch and Sufu have also been implicated as primary factors contributing

to the development of Hh-dependent medulloblastomas (MB) and rhabdomyosarcomas
(RMS)

7-10

. Studies have also identified several ligand-dependent mechanisms that

contribute to constitutive pathway activation. These include autocrine, paracrine, and
reverse-paracrine signaling modalities and have been implicated in a variety of human
cancers, including pancreatic adenocarcinoma

11-13

, gastrointestinal

14

, prostate

15-17

,

breast 18, 19, colon 12, 20-22, and hematologic cancers 23, 24. It is important to note that while
these ligand-dependent mechanisms may contribute to tumor growth in these tissues; it
is unclear whether cancers that exhibit these forms of aberrant signaling can be defined
as Hh-dependent. More detailed descriptions of the ways in which Hh signaling
contributes to human cancer and cancer stem cell populations can be found in several
recently published review articles

25-30

.

2.2 Resistance to Smo Antagonists
To date, several Hh pathway inhibitors that target Smo have progressed from
preclinical development and into clinical trials; however, the development of resistance
to these compounds has become a major hurdle for their continued development
most

advanced

of

these

compounds,

the

small

molecule

25

. The

GDC-0449

(Vismodegib/Erivedge™), was approved by the FDA for the treatment of metastatic
BCC; however, the trials against MB were less successful 31. Although treatment of an
MB patient with GDC-0449 also demonstrated initial positive results, relapse occurred
when a point mutation in Smo (D473H), the molecular target of GDC-0449, rendered the
patient insensitive to further GDC-0449 treatment (Figure 2A)

32-34

. The preclinical

evaluation of NVP-LDE225, a small molecule pathway inhibitor under development by
Novartis, in murine models of Hh-dependent MB demonstrated tumor regrowth following
initial regression, indicating the development of resistance for this compound as well

4

35

.

In these studies, treatment with NVP-LDE225 resulted in chromosomal amplification of
Gli2 and downstream re-activation of Hh signaling, as well as additional point mutations
in Smo

35

. In addition to the development of resistance in MB, a recent study reported

that 21% of patients receiving continuous GDC-0449 treatment for BCC developed
regrowth of at least one BCC

36

. While the molecular mechanisms that govern this

secondary acquired resistance have not been described, the results suggest that
resistance to Smo antagonists in BCC patients will also be an issue moving forward.

Figure 2. Cellular mechanisms of resistance to Hh pathway inhibitors.

Gli: Glioma; P-

gp: P-glycoprotein; PI3K: Phosphoinositide 3-kinase; Ptch: Patched; S6K1: S6 kinase 1.

Additional mechanisms of tumor resistance independent of canonical Hh
signaling have also been reported for Smo antagonists (Figure 2B). Treatment with IPI926 (Saridegib), a semi-synthetic derivative of a natural product Hh pathway inhibitor
cyclopamine (Cyc), resulted in decreased tumor size and prolonged survival in mouse
models of MB; however, resistance to this compound also developed

37

. In contrast to

both GDC-0449 and NVP-LDE225, the resistance for IPI-926 was unrelated to either Gli
amplification or Smo mutations

37

. Follow-up studies with IPI-926 linked resistance to

induction of P-glycoprotein (P-gp) in the tumor cells, suggesting that its decreased
activity was a result of active efflux from the tumor. MB tumors resistant to NVP-LDE225
demonstrated upregulation of components in the phosphoinositide 3-kinase (PI3K)

5

pathway 35. PI3K signaling was previously shown to enhance Gli-dependent transcription
when SHh is present at low levels, suggesting PI3K signaling may partially compensate
for inhibition of Hh signaling by Smo antagonists to promote tumor re sistance

38

. In

esophageal adenocarcinoma (EAC), the mTOR pathway component S6 kinase 1 (S6K1)
phosphorylates Gli1, resulting in its Smo-independent dissociation from Sufu and
activation of Hh signaling

39

. Although this mechanism has not been explored in other

Hh-dependent cancers, it provides evidence of another mechanism that is capable of
promoting resistance to Hh pathway inhibitors that function at or prior to the leve l of
Smo. The inflammatory cytokine osteopontin (OPN) has also been shown to activate Glimediated transcription through a non-classical mechanism by modulation of Akt/GSK3β
signaling

40

. OPN inactivates GSK3β, which ultimately results in Sufu/Gli dissociation

and accumulation of GliA within the nucleus. Interestingly, OPN also up-regulated P-gp
through a Gli-dependent process, suggesting that it may mediate resistance to Smo
antagonists through multiple distinct mechanisms.
3. Small Molecule Smo Antagonists
3.1 Current Status of Important Smo Antagonists
The first-in-class Hh pathway inhibitor, GDC-0449 (2, Figure 3), was a product of
collaborative research by scientists at Curis and Genentech

41

. A series of iterative

medicinal chemistry studies optimized the initial lead compound (1, Figure 3) for
potency, pharmacokinetic (PK) and physicochemical properties to provide GDC-0449 as
a potent inhibitor of Hh signaling (IC 50 values = 3 - 22 nM). Currently, it is approved for
the treatment of advanced/metastatic BCC unmanageable by surgery or radiation
therapy 42. As noted above, these initial successes of GDC-0449 have been countered
by the emergence of resistant forms of Smo that result in its complete loss of efficacy

32

.

Even with the ongoing resistance issues, there is still continued interest in GDC-0449 for

6

several indications as evidenced by currently active clinical trials in which it is being
studied as both monotherapy or in combination to evaluate its safety and efficacy.
Moreover, several trials are underway to assess drug interactions and determine
appropriate drug regimens. Researchers at Genentech seeking to identify structurallyrelated compounds that could inhibit Smo D473H and E518K screened a panel of 53
compounds exhibiting high potency against wild type Smo for their activity against the
mutant receptors

33

. Among these, compound 3 (Figure 3) was selected for further

evaluation due to its robust activity against both wild-type and Smo D473H (IC50 values =
300 nM and 700 nM, respectively) and its enhanced half-life (22 hrs). Compound 3
reduced tumor volume in subcutaneous allografts of the murine Hh-dependent MB tumor
line SG274 following oral administration (100 mg/kg, once daily [q.d.] dosing); however,
neither additional studies nor clinical trials for this compound have been reported

33

.

The second small-molecule inhibitor of Hh signaling that has demonstrated
promising clinical efficacy is NVP-LDE225 (Sonidegib, Erismodegib), a meta-bisphenyl
carboxamide compound developed by Novartis (5, Figure 3)

43

. NVP-LDE225 was

recently advanced to Phase III studies for advanced BCC and a phase III study for
relapsed MB is being initiated to study the comparative safety and efficacy of NVPLDE225 and Temozolomide (TMZ). Additionally, volunteers are currently being recruited
to evaluate efficacy against new indications such as resectable pancreatic cancer,
relapsed acute leukemia, myelofibrosis and Ptch- and Smo-mutant-activated solid and
hematological tumors. Although clinical resistance has not been reported for NVPLDE225, the development of multiple forms of resistance to the compound in mouse
models of MB remains a critical concern for this scaffold.

7

Figure 3. General structural optimization of GDC-0449 and NVP-LDE225.
Cyclopamine (6, Figure 4), an alkaloid natural product derived from corn lilies,
was the first known small-molecule Hh inhibitor. Extensive research using this prototype
Hh/Smo inhibitor not only led to crucial revelations about multiple binding sites,
mechanisms of SMO activation and post binding cellular events

44-46

, but also pushed

forward the search for related small-molecule inhibitors for dysregulated Hh pathway
signaling

44-48

. Due to poor physicochemical properties and moderate activity, Cyc was

unsuitable as a clinical candidate

49

; however, second and third generation Cyc

analogues developed by Infinity Pharmaceuticals improved on the core scaffold and
ultimately resulted in IPI-926 (7, Figure 4), a clinical candidate that demonstrated
improved potency and drug-like properties

37, 50

. When tested in mouse MB allograft

models, IPI-926 demonstrated complete regression upon multi-day oral administration
and abrogated tumor recurrence during a 21-day post treatment period. Despite the
initial promise, IPI-926 failed to deliver satisfactory results in Phase II clinical trials for
pancreatic cancer, inoperable chondrosarcoma and myelofibrosis

51

. It is important to

note that, to date, IPI-926 has not been evaluated in forms of human cancer generally
considered to be Hh-dependent. Although the initial success of IPI-926 suggests the

8

potential clinical efficacy of this class of pathway inhibitor , further development of this
scaffold has been nominal.

Figure 4. Structures of Cyc and its key analogues.
Researchers at the University of Pennsylvania described medicinal chemistry
efforts to identify the Hh inhibitory pharmacophore of Cyc and ultimately developed a
simplified analogue (8, Figure 4) inspired by the Cyc structure

52

. Key modifications

included replacement of the C-nor-D-homo steroidal structure with an androstane ring
system, the piperidine ring with a pyridine moiety and homoallyl alcohol by a phenol.
Analogue 8 and its precursor molecules showed comparable inhibition of Hh signaling in
reporter gene luciferase assays (IC 50 values not reported). Further, analogue 8 was
equipotent to Cyc in a cell viability assay in MB and three times more potent than Cyc in
a granule neuron precursors proliferation assay 52. More recently, the preparation and in
vitro evaluation of a series of Cyc analogues incorporating an exocyclic olefin ( 9a & 9b,
Figure 4) were reported by researchers at the University of Leipzig 53, 54. Both analogues
were significantly more active at inhibiting pathway signaling in Shh-Light II cells, an Hhdependent clonal mouse fibroblast cell line incorporating a stably transfected Glidependent luciferase reporter (10- to 25-fold) with the most potent analogue
9

demonstrating an IC50 against Hh signaling of 0.2 µM

54

. Interestingly, removal or

truncation of the piperidine ring abolished the anti-Hh activity of the exo-Cyc analogues,
suggesting this functionality is essential for the Hh inhibitory activity of the Cyc scaffold
54

. A comprehensive description of other Cyc analogues can be found in a previously

reported review 55.
3.2 Additional Smo Antagonists
3.2.1 Other Key Smo Antagonists in Clinical Trials
The results of a medicinal chemistry program at Pfizer designed to improve the
metabolic profile and enhance the solubility of a class of benzimidazole inhibitors of Hh
signaling culminated in PF-04449913 (10, Figure 5) a potent, urea-based inhibitor of Hh
activity (IC50 = 5 nM)

56

. PF-04449913 demonstrated improved PK parameters, including

a predicted half-life of 30 h and an oral bioavailability of 55% in humans

56

. Although

detailed descriptions of the in vivo activity of this compound have not been disclosed, it
has been advanced into multiple Phase I and II clinical trials for the treatment of acute
myeloid leukemia and high-risk myelodysplastic syndrome either alone or in combination
with other agents. Its efficacy in preventing or decreasing disease relapse in acute
leukemia patients who have undergone donor stem cell transplant is also a current topic
of investigation. Researchers at Pfizer have also reported on the preclinical development
of another potent small-molecule Smo antagonist, PF-5274857 (11, Figure 5)

56

. PF-

5274857 specifically binds to Smo, presumably in the GDC-0449/Cyc binding region,
with high affinity (Ki = 4.6 nM). PF-5274857 demonstrated potent pathway inhibition in
vitro and in an in vivo model of Hh-dependent MB with IC50 values of 2.7 and 8.9 nM,
respectively 57. In vivo inhibition of Hh signaling following oral administration (30 and 100
mg/kg) correlated well with increased survival and significant concentrations of intact PF-

10

5274857 was measured in the cerebrospinal fluid, indicating pharmacologically effective
57

doses achieved blood-brain barrier penetration

.

Researchers at Novartis have recently detailed lead optimization studies on their
initial substituted phthalazine series that ultimately led to the identification of 1 piperazino-4-benzylpyridazine NVP-LEQ506 (12, Figure 5) as a potent pathway inhibitor
currently in clinical development

58, 59

. NVP-LEQ506 demonstrates potent inhibition of

pathway signaling in vitro against both wild-type and D473H Smo (IC50 values ~1 and 96
nM, respectively). Competitive displacement assays demonstrated that NVP-LEQ506
bound with high affinity to human Smo (IC 50 = 2 nM) and in vitro PK assays showed its
enhanced solubility and minimal hERG binding. Preclinical PK studies acr oss multiple
species demonstrated that NVP-LEQ506 possesses good bioavailability, low clearance,
and the ability to cross the blood-brain barrier

59

. Finally, NVP-LEQ506 reduced Gli

mRNA expression and promoted tumor regression in a murine allograft of Hh-dependent
MB following oral dosing (10 – 40 mg/kg, q.d. dosing).

Figure 5. Additional Smo antagonists under clinical development.
TAK-441

(13,

Figure 5) was developed by researchers at Takeda

Pharmaceuticals by optimizing a novel pyrroloquinoline-one hit compound generated in
an high-throughput screening (HTS) effort

60-63

11

. During lead optimization, the core N-

methylpyrrolopyridine scaffold was utilized to achieve optimal PK properties

61

. TAK-441

is a potent inhibitor of Hh signaling in vitro (IC50 = 4.6 nM) that completely abrogated
tumor growth in an Hh-dependent model of MB following oral administration (25 mg/kg,
twice daily [b.i.d.] for 14 days) 61. Interestingly, even though TAK-441 shares the GDC0449/Cyc binding site on Smo, it bound wild-type Smo and Smo D473H with comparable
affinity (Kd values = 1.3nM and 7.8nM respectively) and maintained potent inhibition of
pathway signaling in vitro in the presence of Smo D473H (IC 50 = 79 nM)

62

. In a separate

study, promising preclinical data was reported in delaying progression of castrationresistant prostate cancer in vivo (10 mg/kg or 25 mg/kg q.d. dosing for 7 days)

64

.

Athough TAK-441 had advanced into clinical trial, following its initial Phase I Trial,
Takeda Pharmaceuticals discontinued its development, citing research and development
priorities in other areas

63

.

LY2940680 (14, Figure 5), a phthalazine-based small molecule Smo antagonist
under development at Eli Lilly was reported as a potent inhibitor of Hh signaling (IC 50 =
2.4 nM) as determined in a MB cell line (Daoy)

65

. It was also reported to retain

functional activity against the resistant D473H Smo mutant; however, specific data has
not been reported in the literature. LY2940680 has also demonstrated efficacy in a
mouse model of Hh-dependent MB following oral administration and is currently in
several Phase I & II clinical trials for the treatment of a variety of human cancers

66

.

Exelixis collaborated with Bristol-Myers Squibb to develop XL-139/BMS-833923
(15, Figure 5) another clinical candidate for Hh inhibition in Phase II trials. It was
reported to inhibit the expression of Hh signaling markers such as Gli1 and Ptch1 in cell
lines expressing either wild type or active mutant forms of Smo (IC 50 value = 6-35 nM)

67

.

Competitive binding inhibition of BODIPY-Cyc to Smo by XL-139/BMS-833923 with an
IC50 of 21 nM was demonstrated by a fluorescence-activated cell sorting-based binding
12

assay. Additionally, it was shown to inhibit in vitro growth of multiple myeloma clones
and colonogenic growth of several tumor cell lines obtained from hematological cancer
patients 67.
3.2.2. Smo Antagonists in Preclinical Development
Researchers at Merck have disclosed the preclinical development of multiple
small-molecule scaffolds as Hh pathway inhibitors 68-71. The discovery and development
of MK-5710 traces its origin to a structure-activity relationship (SAR) study of potent
bicyclic hydantoin Smo antagonists. Overall, optimization of this scaffold afforded
homochiral unsubstituted bicyclic tetrahydroimidazo[1,5-a]pyrazine-1,3(2H,5H)-diones
as Hh pathway inhibitors. The most potent of these, MK-5710 (16, Figure 6) inhibited
pathway signaling with an IC50 of 17 nM and displaced BODIPY-Cyc from Smo with high
affinity (IC50 = 13 nM). The in vivo preclinical assessment of MK-5710 revealed favorable
PK properties (oral bioavailability and low clearance) and potent Hh inhibitory activity
(40-160 mg/kg, b.i.d.) against a murine allograft model of Hh-dependent MB

69

. In

addition to MK-5710, a collaborative screening and lead optimization effort identified a
class of piperazinyl ureas as potent inhibitors of Hh signaling

70

. The most active

analogues in this series (17-18, Figure 6) inhibited pathway signaling with IC 50 values of
5 nM and displaced BODIPY-Cyc from Smo (IC50 values = 3 and 13 nM, respectively).
Further development of this scaffold to improve both potency and PK properties focused
on iterative modifications to the “left-side” biaryl moiety, the central piperazine, or the
“right-side” cyclohexyl ring

71

. The culmination of these modifications resulted in

compound 19 (Figure 6), which inhibits Hh signaling with an IC 50 of 4 nM and binds with
high affinity to Smo (IC50 for BODIPY-Cyc displacement = 5 nM); however, further in vitro
and in vivo characterization of these compounds have not been reported.

13

A collaborative effort from researchers of Novartis, Scripps Institute and Harvard
University to screen 50K commercially available small molecules for their ability to inhibit
Hh-Ag 1.5-induced luciferase expression in a stable TM3-Gli-Luc cell line identified
ALLO-1 (20) and ALLO-2 (21) as potent inhibitors of Hh signaling (Figure 6)

72

. Both

compounds exhibited submicromolar potency in a wide-range of in vitro Hh inhibition
assays conducted in the TM3-Gli-Luc cells. As an example, IC50 values for ALLO-1 and
ALLO-2 against Hh signaling induced by overexpression of wild-type Smo were 410 and
41 nM, respectively. In addition, only a modest two-fold reduction in activity against the
mouse homologue of Smo D473H (D477G) overexpressed in TM3-Gli-Luc was seen for
ALLO-1 (IC50 = 1 µM) and ALLO-2 (IC50 = 83 nM) compared to the 175-fold loss in
potency demonstrated for KAAD-Cyc analogue

72

. Anti-proliferation assays in murine

Ptch1+/-p53-/- MB cells overexpressing wild-type Smo or Smo D477G demonstrated GI50
values comparable to the IC50 values obtained in the Hh-dependent TM3 cell line.
Mechanism of action studies suggested that these analogues occupy binding sites on
Smo distinct from that of either the well-characterized Smo agonist SAG or Cyc. Finally,
it is noteworthy that ALLO-2 is structurally similar to kinase inhibitors but didn’t
demonstrate significant inhibition of a 99-kinases panel even when tested at high
concentrations (5 µM)

72

.

Researchers at Oslo University identified MS-0022 (22, Figure 6) as an Hh
pathway inhibitor via a screen of 12K compounds for their ability to prevent Hhdependent differentiation of C3H10T1/2 cells

73

. MS-0022 demonstrated an IC50 of 100

nM against pathway signaling and modest anti-proliferative effects across several cancer
cell lines including pancreatic adenocarcinoma, prostate carcinoma and melanoma. A
decrease in tumor volume of 38% was reported following intraperitoneal (i.p.)
administration of MS-0022 in a xenograft model of pancreatic adenocarcinoma (50

14

mg/kg, q.i.d.). Studies detailing the mechanism of action for this molecule suggested a
dual Smo inhibition (IC50 = 259 nM for competitive displacement of BODIPY-Cyc)
accompanied by micromolar activity against downstream components of the Hh
signaling cascade. Further experiments are warranted to clarify the specific molecular
effects of this compound

73

.

Screening of the Novartis chemical compound collection resulted in the
identification of LAB687 (23a, Figure 6) as a micromolar inhibitor of Hh signaling (IC 50
1.2 µM). Interestingly, this molecule had been originally synthesized as a nanomolar
inhibitor (IC50 0.9 nM) of microsomal triglyceride transfer protein (MTP). As SAR studies
were carried out to prepare selective Hh antagonist based on this scaffold, two
derivatives exhibiting nanomolar Hh inhibition and minimal MTP activity measured were
generated. In a Gli-luciferase reporter gene assay in TM3 cells, IC 50 values for LAB687
derivative 1 and LAB687 derivative 2 (23b and 23c, Figure 6) were calculated to be 8
nM and 17nM respectively

74

. It is noteworthy that this class of ortho-bisphenyl

carboxamide is closely related to clinical candidate NVP-LDE225 that represents the
meta-bisphenyl carboxamide family of analogues.
uHTS screening of Wuxi’s screening collection utilizing Shh-Light II cells
amounted to the identification and development of 4-[3-(quinolin-2-yl)-1,2,4-oxadiazol-5yl]piperazinyl urea class of analogues. Optimization of this class was performed through
SAR study leading to improved derivatives Wuxi 91 and Wuxi 94 ( 24a and 24b, Figure
6). Both analogues demonstrated IC 50 values of 5 nM in Gli-dependent reporter gene
assay conducted in Shh-Light II cells. Smo binding IC 50 values for these derivatives
when measured in presence of 2% FBS were determined to be 3 nM and 13 nM for
Wuxi 91 and Wuxi 94 respectively. However, based on PK assessment of the potent

15

derivatives, Wuxi 94 was shown to possess better intrinsic clearance rate in rats and
dogs 70.

Figure 6. Structures of synthetic Smo antagonists in preclinical development.
A high content screen of FDA approved drugs, clinical candidates, and small
molecules with known biological activity was conducted by researchers at Harvard
University to identify compounds that inhibited Smo accumulation in the p rimary cilia

75

.

This screen identified two small molecules, DY131 (25, Figure 7) and SMANT (26,
Figure 7), as modest inhibitors of pathway signaling (IC 50 values = 0.8 – 2 and 1.1 – 3
µM, respectively). DY131 was originally prepared as an Estrogen Related Receptor
agonist, but within the context of Hh inhibition it was shown to function via direct binding
to Smo at the GDC-0449/Cyc binding site (as measured by displacement of BODIPYCyc). In addition, inhibition of Hh signaling by DY131 was significantly reduced in the
presence of a ligand-independent, oncogenic mutant of Smo (SmoM2). By contrast,
16

SMANT functionally inhibited Hh signaling induced by both wild-type Smo and SmoM2 at
comparable concentrations and did not compete for Smo binding with Cyc, suggesting a
novel mechanism of action for this scaffold

75

.

Figure 7. Structures of synthetic Smo antagonists in preclinical development.
A similar high-content screen designed by scientists at the University of
California at San Francisco to select small molecules that inhibit Smo translocation to
the cilia and/or ciliogenesis identified ten compounds including SA1 and SA4 (27a and
27b respectively, Figure 7) as modest inhibitors of Hh signaling (IC 50 value range 0.92 –
19 µM) that function via inhibition of Smo localization in the cilia

76

. All ten compounds

reduced Gli1 mRNA expression in Ptch1-/- mouse embryonic fibroblasts (MEFs) and
17

BCC cells, but only compounds SA1-9 displaced BODIPY-Cyc from Smo, demonstrating
that they function via direct binding to Smo. Nonetheless, although SA10 (27c, Figure 7)
did not displace BODIPY-Cyc, it was inactive in Sufu-/- cells, indicating that it also
functions at the level of Smo, albeit through an undefined mechanism. In addition, SA110 (25 µM) inhibited Hh signaling in the presence of the oncogenic SmoM2 construct.
Finally, this screen also identified two other small molecules that inhibited ciliogenesis;
however, neither of these compounds inhibited Hh signaling in cell culture

76

.

Based on the knowledge that many of the Smo antagonists share structural
features and bind in the same location on the receptor, a small molecule Smo antagonist
pharmacophore was generated and used by a group at the Centre National de la
Recherche Scientifique as the basis for a virtual screening effort to identify novel
inhibitory scaffolds 77, 78. Based on the screening results, the acylthiourea MRT -10 (28a,
Figure 7) and its corresponding acylurea MRT-14 (28b, Figure 7) were synthesized and
validated as Hh pathway inhibitors (IC 50 values = 0.64 and 0.16 µM, respectively)

77

. In

addition, both MRT-10 (IC50 = 0.5 µM) and MRT-14 (IC50 = 0.12 µM) displaced BODIPYCyc from Smo at concentrations that correlated well with their Hh inhibitory activity.
Additional medicinal chemisty studies on this scaffold resulted in the identification of
MRT-83 (29, Figure 7), which demonstrated an enhanced ability to inhibit Hh signaling
(IC50 = 15 nM), prevent proliferation of cerebellar granule cell precursors (IC 50 = 6 nM),
and displace BODIPY-Cyc from Smo (IC50 = 5 nM)

78

.

A fragment-based design approach was applied towards the discovery and
development of novel N-(2-pyrimidinylamino) benzamide derivatives as potent inhibitors
of Hh signaling by researchers at Jiangsu Pharmaceutical 79, 80. Combining key structural
features of Smo antagonists such as ALLO-2 and NVP-LDE225, lead compound 6a (30,
Figure 7) was designed and synthesized

79

18

. Interestingly, this compound exhibited

greater potency (IC50 = 1.3 nM) as compared to NVP-LDE225 (IC50 5.5 nM) and GDC0449 (IC50 7.2 nM) in Hh-dependent cells. Extensive SAR studies guided modifications
to the terminal aromatic rings ultimately resulted analogue 3c (31, Figure 7), which
demonstrated comparable potency (IC50 1.3 nM) and improved permeability (AlogP 3.6)
80

. Continuing the search for improved leads based on this scaffold, an additional series

of analogues incorporating a pyrrolotriazine isostere in lieu of the pyrimidine was
prepared and evaluated. Many of the derivatives from this class demonstrated potent Hh
inhibition (IC50 range 0.62 – 12.3 nM); most notably, compound 19a (32, Figure 7) not
only exhibited potent anti-Hh activity (IC50 = 0.83 nM), but also superior in vivo plasma
exposure and an increased half-life

81

. To date, additional in vitro assays or in vivo

studies to assess Hh inhibitory efficacy and tumor regression have not been reported for
these compounds.
Several sterol based Smo antagonists have also been recently identified by
several different academic research groups

82-84

. The azasterol 22-NHC (33, Figure 8)

inhibits Hh signaling with an IC 50 of 3 µM and does not affect the interaction between
Smo and other known Smo inhibitors acting on the TM region of Smo

82

. The synthetic

glucocorticoids Budesonide (34a) and Ciclesonide (34b) were identified as pathway
inhibitors through their ability to inhibit Smo ciliary accumulation (Figure 8)

83

. In a panel

of in vitro assays, Budesonide demonstrated modest and comparable inhibition of
pathway signaling against both wild-type and D473H Smo (IC50 values ~50 µM). The
sterol-based Smo antagonists, 20(R)-yne (35) and 20-keto-yne (36), were identified as
modest Hh pathway inhibitors with IC50 values of approximately 5 – 10 µM (Figure 8)

84

.

In addition, both 35 and 36 inhibited Smo D477G-mediated pathway inhibition at levels
comparable to their inhibition of wild-type Smo (~75% inhibition of signaling at 25 µM).
Follow-up studies for these sterols have demonstrated that, in contrast to the Smo

19

antagonists described above, each of these function through direct binding to a newly
identified binding site on the extracellular cysteine rich domain of Smo (CRD, described
in more detail in Section 3.3 below).

Figure 8. Sterol related Smo antagonists.
3.3 Identification and Mapping of Smo Binding Sites
Numerous groups have actively sought to probe several distinct small molecule
binding sites on Smo in order to: (i) facilitate the rational design of future Smo
antagonists; and (ii) better understand to what extent endogenous small molecules
regulate pathway signaling via direct binding to Smo

82-88

. More detailed information on

Smo binding sites could potentially mitigate the problem of drug resistance and permit
combination therapy or allosteric modulation for improved potency. The first attempts to
identify a small molecule binding region on Smo utilized photoaffinity labeling studies
with an azide-I125 labeled Cyc analogue and deletion mutants of Smo to localize the Cyc
binding pocket to the heptahelical bundle of Smo

46

. Since that time, a similar BODIPY-

labeled Cyc analogue has been routinely utilized to demonstrate tha t multiple small
molecule Smo antagonists and agonists bind in the same region as Cyc. Further
information on the GDC-0449/Smo binding site came with the identification that the Smo
D473H mutant resulted in the loss of both affinity and efficacy. Further evidence to

20

corroborate this binding site was achieved by mapping the location of D473 to the Cterminal end of transmembrane loop 6 on a rhodopsin-based molecular model of Smo 34.
Indeed, the Asp residue was found to occupy an extracellular site facing the central
binding cavity of Smo. Interestingly, this position is a highly conserved region among
Smo orthologs and Wnt signaling proteins that belong to the Frizzled family 87.
Table 1. Key Hh pathway inhibitors that function through direct inhibition of Smo.
GDC-0449

IC50
a
wild-type Smo
3-22 nM

IC50
a
D473H/D477G
Loss of activity

IPI-926

7 nM

244 nM

Clinical (Phase II)

37, 50

NVP-LDE225

2.5 nM

Loss of activity

Clinical (Phase III)

43, 89

PF-04449913

5 nM

ND

Clinical (Phase II)

56

NVP-LEQ506

1 nM

96 nM

Clinical(Phase I)

59

TAK-0441

4.6 nM

79 nM

Clinical (discontinued)

LY2940680

2.4 nM

Active

b

XL-139/BMS

21 nM

PF-5274857

Compound

Development Status
Clinically Approved

Reference
41

61, 62

Clinical (Phase II)

66

ND

Clinical (Phase II)

67

2.7 nM

ND

Preclinical

57

MK-5710

17 nM

ND

Preclinical

69

19

5 nM

ND

Preclinical

71

ALLO-1

410 nM

1 µM

Preclinical

72

ALLO-2

41 nM

83 nM

Preclinical

72

MS-0022

100 nM

ND

Preclinical

73

LAB 687

1.2 µM

ND

Preclinical

74

23b

8 nM

ND

Preclinical

74

23c

17 nM

ND

Preclinical

74

Wuxi 91

5 nM

ND

Preclinical

70

Wuxi 94

5 nM

ND

Preclinical

DY 131

0.8-2 µM

ND

Preclinical

70
75

SMANT

1.1 – 3 µM

ND

Preclinical

75

MRT-83

15nM

ND

Preclinical

78

32

0.83 nM

ND

Preclinical

81

33

3 µM

ND

Preclinical

82

Budesonide

50 µM

50 µM

Preclinical

83

35

5-10 µM

~30 µM

Preclinical

84

36
5-10 µM
~30 µM
Preclinical
Values assessed using different assay methods described in text
b
Specific IC50 values were not provided
ND=not determined/ reported

84

a

More detailed structural information about the small-molecule binding site(s) on
the 7TM domain region of Smo has come from two recently published co-crystal
21

structures describing this region in complex with either LY2940680

87

or Cyc 88. A lipidic

mesophase method was utilized to solve a co-crystal structure of an engineered human
Smo receptor in complex with LY2940680 to 2.5 Å (Protein Data Bank ID 4JKV)

87

. The

overall structure of Smo is characterized by an elaborate arrangement of long
extracellular loops that are stabilized by four disulfide bonds and within this context, the
binding pocket of LY2940680 is at the extracellular end of the 7TM helical structure and
is linked to the extracellular environment by a small opening characterized by the
extracellular domain and extracellular loops 2 and 3. Two water molecules form a
structured hydrogen-bonding network between R400, H470, D473, E518, and N521 that
help define the binding pocket; however, they do not make direct interactions with
LY2940680. Key hydrogen-bonding interactions occur between the guanidinium of R400
and the phthalazine nitrogens and between the carboxamide of N219 and the carbonyl
oxygen. Direct contact between LY2940680 and D473 is minimal (4.04 – 4.31 Å
between the aspartic acid carboxylate and the Smo antagonist) and these limited
interactions help to explain how the compound retains potent activity in the presence of
Smo D473H (Figure 9). More recently, a lipidic cubic phase method was utilized to solve
the co-crystal structure of Cyc in complex with the same engineered human Smo
receptor (3.2-4.0 Å)

88

. The Cyc binding region was localized to the same vicinity as

LY2940680; however, the low resolution of the complex prevented the definitive
identification of the Cyc orientation within the binding pocket. The authors provide
evidence that the pyridine ring is positioned towards the solvent exposed extracellular
space of the binding region, but further refinement is necessary to conclusively identify
the binding site and key molecular interactions between Cyc and Smo.
In addition to small molecule binding sites within the 7TM domain of Smo,
several independent research groups have explored the ability of Hh pathway

22

modulators to exert their activity through direct binding interactions with the extracellular
cysteine rich domain (SmoCRD)

82-86

. These studies have all focused on exploring the

role of the SmoCRD in binding Hh agonists and antagonists with a sterol or sterol-like
scaffold. Initial assays utilizing Smo deletion and/or ligand affinity protocols
demonstrated that the Hh agonist properties of oxysterols (OHCs) are mediated through
direct binding to the SmoCRD and that small molecules that bind in this lo cation can be
agonists or antagonists, depending on structure

82-85

. In addition, these experiments

provided strong evidence that the OHC binding site is localized to “site 1” of the CRD, a
hydrophobic pocket formed by side chain α-helices that is analogous to the lipid-binding
grove previously identified in the Frizzled CRD. Two recent reports have provided
additional detailed structural insights into this small molecule binding site via the crystal
structure of the zebrafish SmoCRD (zSmoCRD, 2.3 Å resolution)
solution structure of the Drosophila SmoCRD (dSmoCRD)

84

and the NMR

86

. Molecular docking studies

between zSmoCRD and 20(S)-OHC, a well-characterized pathway agonist, suggested
the tetracyclic core of the OHC scaffold lies in the base of the lipid -binding groove at site
1 lined by W87 and L90. This docking model predicts that the 3β-hydroxy of 20(S)-OHC
orients towards helix 1 residues L90 and N92, while the 20( S)-hydroxy and side chain
are in close proximity to residues P142 and F144

84

. Mutagenesis studies on residues

within the predicted binding site supported the structure -based model of the OHC
binding pocket; however, specific molecular interactions between the OHC scaffold and
these residues have not been detailed

84

. The solution structure of Budesonide in

complex with dSmoCRD further supports the site 1 lipid-binding groove as the key
binding pocket for sterol-based pathway modulators of Hh signaling within the CRD

86

.

Chemical shift perturbations identified potential binding interactions between budesonide
and R161, W109, G111, and L112, all of which reside within site 1 and were previously
identified as key for 20(S)-OHC binding.
23

Figure 9. Key binding site interactions between Smo and LY2940680.
4. Small Molecule Non-Smo Antagonists
4.1 Compounds Acting Upstream of Smo
Maturation of a fully active Hh ligand results from a series of post-translational
modifications of the secreted protein, including the covalent attachment of a palmitoyl
moiety at the N-terminus

90

. For this modification, hedgehog acyltransferase (Hhat)

catalyzes the attachment of a palmitoyl group to the N-terminal cysteine of SHh through
an amide bond. A high-throughput screen (~64K compounds) was conducted to identify
small molecules that inhibit Hhat-mediated SHh palmitoylation

91

. Secondary analysis of

the hit compounds to identify potent inhibitors with promising drug -like properties
identified four structurally-related thiophene piperidines with IC50 values ranging between
0.2-5µM. One compound RU-SKI 43 (37, Figure 10) with an IC50 of 0.85 µM was chosen
for further evaluation as a Hhat inhibitor. It was a noncompetitive inhibitor (Ki = 6.9 µM)
with respect to [I125] iodo-palmitoyl CoA and an uncompetitive inhibitor with respect to
SHh; moreover, inhibition by RU-SKI 43 was selective to Hhat and not a broad activity
against other fatty acyltransferases. Finally, several cellular assays demonstrated that
the Hh inhibitory activity of RU-SKI 43 is mediated at the level of SHh

91

.

Several macrolactones that inhibit Hh signaling through direct binding to SHh
were identified in a microarray-based screen (10K compounds) by researchers at the
Broad Institute

92

. Optimization of the lead scaffold led to robotnikinin (38, Figure 10),
24

which bound to SHhN (an active N-terminal fragment of SHh) with a Kd value of 3.1 µM
as determined via surface plasmon resonance. Binding to Hh ligand is thought to induce
conformational changes in the protein preventing its interaction with Ptch and repressing
SHh-mediated Gli overexpression. When tested in a Gli-luciferase reporter gene assay
in Hh-dependent cells, it inhibited Hh signaling with an IC50 of 4 µM

92

. Further SAR

studies on the macrolactone scaffold produced a series of analogues including
BRD6851 (39, Figure 10), as an Hh inhibitor with improved activity (IC 50 = 0.4 µM)

93

.

Interestingly, cellular studies into the mechanism of BRD6851 suggested it functions at
the level of Smo; however, these studies were indirect and displacement of a known
small molecule Smo antagonist by BRD6851 has not been demonstrated. To date, in
vivo data in Hh-dependent models of cancer have not been reported.

Figure 10. Structures of inhibitors upstream of Smo.
Computational approaches to design small molecules that perturb SHh/Ptch
binding interactions have been undertaken at Gyeongsang National University in Korea
94, 95

. First, robotnikin and related analogues were used to develop a 3D-pharmacophore
25

model that was used in a virtual screening of >100K to identify structurally-related small
molecules as possible Hh pathway inhibitors

94

. This screen and follow-up modeling

studies suggested that GK 03795 (40, Figure 10) should bind SHh in the same location
as robotnikin. A second virtual screen of >200K utilizing a computational model of key
SHh/Ptch binding interactions was performed to identify small molecules that disrupt this
specific interaction. Additional docking and computational analysis of two hit compounds,
BAS 13382637 (41) and BAS 06350510 (42), suggest their potential to bind SHh with
high affinity (Figure 10) 95. To date, experimental verification of these simulation results
in in vitro or in vivo assays has not been reported.
4.2 Compounds Acting Downstream of Smo
Two small molecules, GANT-58 & GANT-61 (43 & 44, Figure 11), were identified
as inhibitors of Gli-mediated transcription through a screen in HEK293 cells
overexpressing Gli1 by researchers at the Karolinska Institutet

96

. Both compounds

inhibited Hh signaling and Gli expression with an IC50 value of approximately 5µM

96

.

Their ability to maintain potent Hh antagonism in Sufu -/- cells verified that these agents
act downstream of Smo. Interestingly, GANT-61 was shown to disrupt Gli1 DNA binding
in live cells.

Selectivity for Hh-mediated Gli expression was corroborated using a

microarray analysis in which neither analogue was active against several unrelated
signaling pathways. In addition, both compounds prevented the formation of dominantactive Smo transfected NIH3T3 colonies in soft agar. Finally, tumor growth regression
and significant decrease in Ptch mRNA level were observed upon treating a mouse
xenograft model of human prostate cancer with GANT-61 (s.c., 2.5 mg/kg, once daily
dosing for 18 days)

96

.

Studies demonstrating interactions between Gli proteins and the transcriptional
coactivator TBP-associated factor 9 (TAF9) prompted the design of a small molecule,
26

FN1-8 (45, Figure 11), which prevents Gli/TAF9 interactions and down-regulates Gli
expression

97

. The structure of this compound developed by researchers at the

University of California at San Francisco was derived as a mimic of the common αhelical ‘FXXɸɸ’ motif contained in many Gli proteins. FN1-8 (15 µM) prevented TAF9
from binding both Gli1 and Gli2 in vitro and led to significant reductions in Gli
transcriptional activity 97. FN1-8 (7.5 or 15 µM) prevented proliferation of non-small cell
lung cancer cells (NSCLC) that over-express either Gli1 or Gli2 and its anti-proliferative
effect correlated well with down-regulation of endogenous Ptch and Gli1 mRNA. Finally,
FN1-8 down-regulated Ptch and Gli1 mRNA and reduced tumor volume in NSCLC
xenografts (50 mg/kg, sc) 97. Subsequent modifications to FN1-8 carried out at St. Jude
Children’s Research Hospital afforded a modest inhibitor of Gli1 transcription factor s
known as NMDA298-1 (46, Figure 11). Extensive SAR for the scaffold demonstrated that
the tyramine amide region of this chiral molecule is essential for its biological activity.
NMDA298-1 activity was selective for Gli1 compared to Gli2 in Hh-dependent cell culture
(IC50 values = 6.9 and ~23.9 µM, respectively). Additional viability studies in cancer cells
(breast, MB, prostate cancer, Burkitt’s lymphoma, hepatocarcinoma, glioma) versus
healthy cells (human skin fibroblasts) established that NMDA298 -1 selectively targets
tumor cells 98.
Historically, arsenicals have been known for their toxicological effects during
embryogenesis; however, arsenic trioxide (ATO) has had pharmacological use in the
clinic as a curative agent for acute promyelocytic leukemia

99

. Based on these seeming

contradictions, the role of several arsenicals in inhibiting Hh signaling was evaluated by
researchers at the Stanford University School of Medicine. Three arsenicals (sodium
arsenite, ATO, phenylarsine oxide) and the most active, ATO, inhibited pathway activity
in an Hh-dependent cell model with an IC50 value of 0.7 µM 100. In murine allografts of

27

Hh-dependent MB, ATO inhibited tumor growth in a dose-dependent fashion following IP
administration (2.5 – 10 mg/kg). In addition, ATO inhibited Smo D477G-mediated Hh
signaling at a level comparable to that for wild-type Smo (IC50 = ~0.8 µM). ATO as a
monotherapy and in combination with other Hh pathway inhibitors has demonstrated
potent anti-Hh and anti-tumor effects in a variety of in vivo models of Hh dependent
cancer 100-102. Most notably, ATO increased survival in an orthotopic model of MB driven
by Smo D477G (IP administration, 7.5 mg/kg, OD) 101. Mechanistic studies on the target
of ATO within the Hh pathway have demonstrated that it directly binds to Gli1, reducing
its transcriptional activity and decreasing expression of Gli target genes

100, 102

.

Figure 11. Synthetic Hh pathway inhibitors that target downstream of Smo.
The pathway inhibitors HPI-1 through HPI-4 (47, 48a-c, Figure 11) were
identified at the Stanford University through a screen of >100K compounds specifically
for their ability to interfere with Hh signaling downstream of Smo

28

103

. Each of these

compounds demonstrated modest inhibition of Hh signaling with an IC50 value range of
1.5 - 7 µM. In addition, these compounds demonstrated selectivity for Hh signaling over
Wnt, PKA and PI3K/MAPK signaling. Interestingly, while each HPI was able to inhibit
pathway activity in the presence of the SmoM2 mutant, only HPI-1 and HPI-4 prevented
SmoM2-dependent proliferation of cerebellar granule neuron precursors. The HPIs are
structurally dissimilar and antagonize the hyperactive signal transduction through varied
subcellular mechanisms even though they all target components downstream of Smo.
The central theme underlying their inhibitory activity is disturbing the processin g,
trafficking and stability of Gli transcription factors

103

. In order to enhance the solubility

and bioavailability profile of HPI-1, researchers at the Johns Hopkins University
formulated it as a polymeric nanoparticle with poly(lactic-co-glycolic acid) conjugated to
polyethylene glycol (PLGA-PEG) to provide NanoHHI 104. In contrast to HPI-1, NanoHHI
formed a uniform suspension in aqueous media, was orally bioavailable, and crossed
the blood-brain barrier

104

. NanoHHI reduced tumor volume in orthotopic models of MB

driven by either wild-type Smo or Smo D477G (IP administration, 30 mg/kg, b.i.d)

104

. In

addition, NanoHHI inhibited in vitro proliferation and in vivo tumor growth and metastasis
of hepatocellular carcinoma

105

.

Naturally occurring flavonoid glycosides from Excoecaria agallocha leaves inhibit
the Hh signal transduction by abrogating Gli1 translocation to the nucleus. Researchers
at Chiba University reported that compounds 1, 2 and 8 (49a-c, Figure 11) antagonize
Gli mediated transcriptional activity with IC 50 values of 0.5, 19.1 and 2.0 µM respectively.
In addition, these compounds exhibit selective cytotoxicity against human pancreatic
cancer cells (PANC1) and human prostate cancer cells (DU145) at low micromolar
concentrations. Further investigation revealed that compound 1 inhibited the expression
of Hh proteins (Ptch and BCL-2) and blocked nuclear translocation of Gli1 in PANC1
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cells in a dose dependent fashion. Further, experiments with siRNA mediated
knockdown of Smo confirmed that Gli1 inhibition is brought about independently of Smo
interference

106

.

4.3 Compounds With Unknown/Undisclosed Target or Indirect Mechanism
Several members of the vitamin D class of secosteroids have also been identified
as modulators of Hh pathway signaling. Vitamin D3 or VD3 (50, Figure 12), a metabolic
precursor to the hormonally active form of vitamin D known as calcitriol, was first
identified as a pathway inhibitor in studies conducted to identify physiological small
molecules that control Ptch-mediated inhibition of Smo 107. VD3 inhibition of Hh signaling
in vitro is modest, with IC50 values reported between 1 and 20 µM

107-111

. VD3 has

demonstrated the ability to significantly reduce in vitro proliferation of Hh-dependent
BCC cell lines and reduce in vivo Gli expression in mouse models of BCC

110

.

Interestingly, while VD3 inhibited the growth of pancreatic cancer cells, it failed to have
an anti-tumor effect in a comparable xenograft model of pancreatic adenocarcinoma

109

.

Initial studies into the mechanism of action for VD3-mediated Hh inhibition suggested
that this activity was at the level of Smo; however, it has also been shown that VD3 can
activate canonical vitamin D receptor (VDR) signaling in these same model systems

108-

110

. Calcitriol (51, Figure 12), generally acknowledged as the physiologically active form

of vitamin D, has also demonstrated the ability to inhibit Hh signaling in vitro and in vivo
in Hh-dependent models of BCC and RMS. Similar to VD3, calcitriol appears to inhibit
Hh signaling at the level of Smo, while also activating the canonical VDR pathway in
these models. Taken together with the additional recent data suggesting complicated
crosstalk between Hh and VDR signaling (reviewed in a previous publication 112), further
explorations into the biological activities of these secosteroids is warranted to more
clearly define the mechanisms that govern their pathway modulation .
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A medicinal chemistry approach undertaken at the University of Connecticut to
design analogues of VD3 that selectively target Hh signaling demonstrated that the
‘northern’ region of VD3, also known as Grundmann’s alcohol (52, Figure 12), retains
~90% of the Hh inhibitory activity of the parent scaffold (IC 50 values = 3.1 and 4.1 µM,
respectively) 111, 113. A subsequent series of VD3 analogues designed to incorporate an
aromatic A-ring isostere that maintains the approximate steric and hydrophobic features
of the natural aliphatic A-ring into the secosteroid scaffold identified compound 53
(Figure 12) as a selective Hh inhibitor with improved potency (IC 50 = 0.74 µM)

113, 114

.

Figure 12. Compounds with indirect/unknown/undisclosed mechanism(s).
Desmethylveramiline (54, Figure 12), a semi-synthetic compound, belongs to the
steroidal family of Hh inhibitors and shares structural features with Cyc. A seven step
derivatization of teratogenic alkaloid veramiline was reported by researchers at
University of Strasbourg. Using relatively straightforward synthetic manipulation of
commercially available starting material, Fernholtz acid, preparation of this analogue
was accomplished with the intention to mimic the complex spatial structure of Cyc 115. At
10 μM, it inhibited ShhN-induced luciferase activity in Shh-Light II cells and SAG-induced
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differentiation of C3H10T1/2 cells by 87 ± 1% and 85 ± 4% respectively. However, the
specific molecular target of this micromolar inhibitor remains undetermined to date.
A screen of FDA approved drugs identified the clinically efficacious antimycotic
drug itraconazole (ITZ, 55, Figure 12) as a potent pathway inhibitor in vitro (IC50 values =
270 – 690 nM, depending on cellular context)

116

. ITZ also inhibits pathway signaling

mediated by Smo D477G at a level comparable to its inhibition of wild -type Smo (IC50
~500 nM)

101

. Treatment with ITZ significantly decreased tumor volume and increased

survival in Smo D477G MB allografts. In addition, oral administration of ITZ (75 mg/kg,
b.i.d) significantly increased survival in an orthotopic model of MB expressing
SmoD477G, highlighting the ability of ITZ to be centrally active against intracranial
tumors. Similar activities for ITZ in Hh-dependent BCCs have also been described 101, 116.
Studies have demonstrated that the Hh inhibitory activity of ITZ is unrelated to inhibition
of 14-α-lanosterol demethylase, the physiological target responsible for its anti-fungal
properties. Further investigations have suggested that it inhibits at the level of Smo;
however, direct binding interactions or displacement of a known Smo antagonist have
not been identified. The results of a Phase II trial into the anti-BCC effects of oral ITZ
demonstrated positive results and the authors note further clinical trials are in the
planning process

117

. It should be noted that ITZ was also recently identified as an

inhibitor of angiogenesis, suggesting its potential application as an anti -cancer
therapeutic via multiple distinct mechanisms of action

118, 119

. A single publication

detailing Hh inhibitory activity for ITZ analogues with modified alkyl side chains has been
reported

120

. These studies demonstrated while small aliphatic groups were well-

tolerated, bulky functional groups in this region completely abolished inhibitory activity.
A recent screen of approximately 20K small molecules followed by SAR studies
on the hit scaffold conducted at the Broad Institute of MIT and Harvard University
32

identified a series of small molecules that incorporate a central eight -membered
heterocycle as inhibitors of pathway signaling 121. The most potent compounds that also
demonstrated promising drug-like solubility, BRD50837 and BRD9526 (56 and 57,
Figure 12), were chosen for additional studies to probe the mechanism of action of this
scaffold (IC50 values = 90 and 60 nm, respectively). Neither compound displaced
BODIPY-Cyc from Smo, suggesting they did not bind in the known Smo binding pocket.
Interestingly, while neither compound inhibited pathway signaling in Ptch -/- cells, they
retained partial activity in SuFu-/- cells, a seemingly contradictory result

121

. It is clear

that further studies are warranted to understand the cellular mechanisms that govern the
Hh inhibitory activity of this scaffold.
Researchers at Novartis recently combined a high-throughput screening effort
with additional in vitro assays to identify novel small molecule modulators of Hh signaling
. Their overall goal was to identify ‘non-Smo’ inhibitors that could then be utilized as

122

chemical probes to identify new drug targets within the pathway. The ultimate result of
these studies was the identification of the cyclohexyl-methyl aminopyrimidine (CMAP)
scaffold represented by 58, 59, and 60 (Figure 13) as inhibitors of Gli-mediated
transcription that function via agonism of the orphan GPCR GPR39. These three
compounds potently inhibited Hh signaling (as measured by down -regulation of a Gli
luciferase reporter) with low nanomolar potency (IC 50 values = 4 -10 nM)

122

. Follow-up

studies with these compounds demonstrated that GPR39 was required for their anti -Hh
activity and it was hypothesized that activation of GPR39 stimulates multiple signaling
pathways to activate MAPK, which directly inhibits the transcriptional activity of Gli
proteins 122.
Researchers at Chiba University reported three naturally occurring molecules
namely colubrinic acid, betulinic acid and alphitolic acid (61, 62 and 63, Figure 13) found
33

in pentacyclic triterpenoids of Zizyphus cambodiana to exhibit Hh inhibitory activity

123

.

These compounds inhibit Gli1 expression with micromolar IC50 values (38-42 μM) and
also exert cytotoxic effects on pancreatic and prostate cancer cells. On the contrary,
they are relatively non-lethal towards non-cancerous cells such as MEFs. Interestingly,
inhibition of Hh signaling by betulinic acid in rhabdomyosarcoma cells is accompanied by
induction of apoptosis

123, 124

. This pharmacological effect could be due to its role in

activation of the Mitogen Activated Protein Kinase (MAPK) pathway as established
earlier in human melanoma cells

125

. Nonetheless, antagonism of Hh signaling was

confirmed by documenting reduction of Hh target genes such as Gli1, Gli2, Ptch1 and
IGF2 in a rhabdomyosarcoma cell line with otherwise increased Hh pathway activity.
Structurally distinct compounds GW3965 and TO-901317 (64 and 65, Figure 13)
are liver X receptor (LXR) agonists that indirectly antagonize the Hh signaling

126

.

Researchers at University of California Los Angeles recorded a dose -dependent and
time-dependent inhibition of Hh responsive genes (Ptch1, Gli1) following treatment in
MEF M210B4 cell line. Using qRT-PCR, greater than 50% inhibition of Ptch1 and Gli1
expression was observed upon treatment with 2 μM TO-901317. Further, gene silencing
experiments confirmed that abolition of LXR activity significantly affected the resultant
Hh modulation. In addition to the in vitro activity, reduction of Hh responsive genes by
TO-901317 was observed in ex vivo as well as in vivo mouse organ cultures. It is
hypothesized that the pharmacological activity of cholesterol depletion due to LXR
activation potentially perturbs the post-translational modification of Hh proteins and
thereby leads to Hh pathway inhibition by TO-901317.
Another interesting small molecule, norcantharidin ( 66, Figure 13), was
developed by researchers in Taiwan as a synthetic derivative of naturally occurring
molecule, cantharidin. Previously, this compound was known to inhibit drug effux pump
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protein, P-gp, making it useful against multidrug resistance

127

. More recently, it was

reported to cause reversal of multidrug resistance in human breast cancer cells
accompanied by downregulation of Shh protein and perturbation of Gli1 nuclear
translocation at 10 μM concentration

128

. In accordance with its effect on P-gp,

concomitant treatment of norcantharidin with Doxorubicine (DOX) also improved
intracellular accumulation of the latter in MCF7 cells resistant to DOX from 30% to 80%.
Other noteworthy pharmacological effects of norcantharidin include inhibition of tumor
angiogenesis by blockade of VEGFR2/MEK/ERK signaling pathways

129

.

Figure 13. Compounds with indirect/unknown/undisclosed mechanism(s) .
A class of compounds with 2, 4 substituted thiazole was identified in a screen of
20,000 heterocycles by researchers at The Scripps Research Institute. Within this class,
JK-184 (67, Figure 13) proved to be nanomolar inhibitor of Gli1 (IC 50 30 nM) as
determined in a Gli dependent luciferase assay. A SAR analysis of this core led to
optimization of the parent scaffold and guided the discovery of other improved
35

antagonists that have been patented. JK-184 exerts potent antiproliferative effects in a
panel of cell lines (IC50 values between 3 nM and 21 nM). Preliminary, mechanistic
characterization suggested that it antagonizes Hh signaling at the level of Gli.
Additionally, Hh downregulatory effect of this compound is mediated indirectly by
inhibition of class IV alcohol dehydrogenase 7 [Adh 7] (Kd = 348 nM)

130

.Further probing

revealed other biological effects mediated by this compound such as microtubule
destabilization to serve as alternate mechanism of action explaining the nanomolar antiproliferation potency 131.
Table 2. Key ‘non-Smo’ Hh pathway inhibitors.
Robotnikinin

IC50
a
wild-type Smo
4 µM

IC50
a
D473H/D477G
ND

Development
Status
Preclinical

92

BRD 6851

0.4 µM

ND

Preclinical

93

RU-SKI 43

0.85 µM

ND

Preclinical

91

GANT-61

5 µM

ND

Preclinical

96

NMDA298-1

6.9 µM

ND

Preclinical

98

ATO

0.7 µM

~0.8 µM

Preclinical

100, 101

HPI-1

1.5 µM

ND

Preclinical

103

Preclinical

104

Preclinical

106
107-110

Cmpd

b

Active

b

NanoHHI

active

49a-c

0.5, 19.1, 2 µM

VD3

1-20 µM

ND

Preclinical

Reference

53

0.74 µM

ND

Preclinical

Calcitriol

0.1 µM

ND

Preclinical

ITZ

0.27-0.69 µM

0.5 µM

Phase II

58

4 nM

ND

Preclinical

122

61-63

38-42 µM

NND

Preclinical

BRD50837

90 nM

ND

Preclinical

123
121

BRD9526

60 nM

ND

Preclinical

121

Preclinical

130

JK 184
30 nM
ND
Values assessed using different assay methods described in text
b
Specific IC50 values were not provided

113
108
101,116, 117

a

5. Biologics as Hh Pathway Inhibitors
In addition to the small molecule Hh pathway inhibitors described above, several
protein-based Hh pathway inhibitors have been described. The best characterized of
these is 5E1, which was initially generated by scientists at Genentech through mouse

36

hybridoma technology utilizing the N-terminus of rat SHh as the antigen

132

. 5E1 inhibits

pathway signaling by preventing Hh ligands from interacting with Ptch through direct
binding interactions with the pseudo active site groove of the Hh ligand

133

. 5E1 binds

with high affinity to human SHh and IHh (KD value ranges = 0.13 – 0.31 and 0.16 – 0.29
nM, respectively) 133, 134. 5E1 also binds to DHh, although at a reduced affinity (KD = 1.7
nM)

133

. The reduced affinity for DHh is likely due to the increased bulk associated with

Asn179 compared to Ala179 found in the binding epitope of SHh

133

. 5E1 is a potent

inhibitor of Hh signaling in multiple Hh-dependent fibroblast cell lines (IC50 values = 0.33
– 12.5 nM)

133, 134

. 5E1 has also demonstrated the ability to inhibit pathway signaling and

decrease tumor volume in colorectal xenografts 12, orthotopic and xenograft models of
pancreatic cancer 135, 136, and medulloblastoma 137, but it has not advanced beyond these
preclinical studies.
A more recent report by researchers at AstraZeneca detailed the development of
a series of human monoclonal antibodies against SHh as potent pathway inhibitors

134,

138

. Xeno-Mouse mice were immunized against human SHh using both recombinant

human SHh and KLH-conjugated SHh. Two of the antibodies generated through this
process, 3H8 and 6D7, were extensively characterized for their SHh-binding and in vitro
anti-Hh and anti-cancer activity. Interestingly, while both antibodies bound with high
affinity to human SHh (Kd values = 36 and 5 pM, respectively) only 6D7 bound IHh (Kd =
34 pM) and neither bound DHh

134

. Both antibodies inhibited pathway signaling in Hh-

dependent cell culture (C3H10T1/2) in the low nanomolar range (IC 50 values = 3.4 nM
and 5.3 nM, respectively) 138. Due to its broader substrate specificity, 6D7 was renamed
MEDI-5304 and further evaluated for its in vivo anti-cancer effects in a compliant model
(HT-29 human cancer cells and MEFs) of colorectal cancer that mimics paracrine Hh
signaling

134

. MEDI-5304 decreased Hh signaling and tumor volume in this model in a
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dose-dependent fashion (0.1-10 mg/kg); however, the overall reduction in Hh pathway
target gene expression and tumor growth was modest (~30 -50% reduction)

134, 138

. In

addition, preliminary toxicology studies in rats and cynomolgus monkeys did not identify
adverse effects up to 75 mg/kg.
6. Conclusion & future directions
Hh signaling pathway inhibitors are being developed in both academia and
industry as potential anti-cancer chemotherapeutics. Thus far, pathway inhibitors have
demonstrated clinical efficacy against cancers in which a specific pathway mutation is
responsible for tumor formation. However, broader applications against other forms of
cancer are yet to be fully explored. The initial development of Hh pathway inhibitors
focused mainly on small molecules antagonists of Smo. In fact, the only pathway
inhibitor approved by the FDA, Vismodegib, also acts by targeting Smo. Unfortunately,
multiple mechanisms of resistance to Smo inhibitors have been reported in the recent
years. Therefore, there is an urgent need to identify and develop novel inhibitors of
pathway signaling that retain activity against resistant forms of Hh driven tumors. Guided
by the current progress towards better understanding of structural and functional
requirements of active molecules, researchers may adopt different strategies to address
this issue. For instance, several research groups are working to develop pathway
inhibitors that function downstream of Smo and retain activity against drug resistant Smo
mutations. Further, the latest characterization of multiple small molecule binding sites on
Smo can be exploited in the structure-based design of improved Smo antagonists.
Nonetheless, to present date, advancement of such newer inhibitors beyond preclinical
and early clinical trials has been nominal. Therefore, there is an immense need for
continued research in this area.
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The following chapters describe the progress towards the identification of novel
small molecule inhibitors of the Hh signaling pathway using a chemical biologydependent drug discovery strategy. Since crystal structures of drug binding receptors
involved in Hh signaling were unavailable prior to 2013, adopting a structure-based drug
discovery strategy was not feasible when these projects were first started. Alternately, a
ligand based drug discovery approach was taken to develop Hh inhibitors based o n two
distinct lead structures namely VD3 and ITZ.
Based on preliminary findings, it was hypothesized that metabolic conversion of
VD3 to its physiologically active form, calcitriol, can occur in cell culture leading to robust
activation of VDR signaling. Over activation of VDR signaling results in hypercalcemia,
hence such off-target effects preclude the clinical use of VD3 as an inhibitor of Hh
pathway. Therefore, the goals of this project were to pursue a SAR study to identify the
Hh inhibitory pharmacophore of VD3 and use this knowledge to improve potency and
selectivity of VD3 based anti-Hh analogues.
Next, based on a comparative analysis of Hh inhibition mediated by ITZ and
other marketed azole antifungal drugs that share common structural features interesting
trends were discovered. This study indicated that integrating structural features of
Posaconazole (PSZ) with ITZ could potentially lead to superior second generation
analogues. Thus, the aim for this project was to synthesize and evaluate ITZ derivatives
with stereochemically defined hydroxylated side chains as mimics of the PSZ side arm.
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CHAPTER II: Design, Synthesis and Evaluation of Vitamin D3 A-Ring Analogues
as Hedgehog Pathway Inhibitors
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1. Introduction

Figure 1. Structure of Vitamin D3 and related compounds.
A recent study demonstrated that vitamin D3 (VD3), a metabolic precursor to
1α,25-dihydroxyvitamin D3 [1α,25(OH)2D3, calcitriol], inhibits the Hh signaling pathway
presumably by binding to Smo (Figure 1)

107

. Previous research into the potential

preventative and therapeutic anti-cancer effects of the vitamin D class of sterols has
focused on 1α,25(OH) 2D3, generally acknowledged as the hormonally active form of
vitamin D. These anti-cancer effects are primarily mediated through the vitamin D
receptor (VDR), a nuclear receptor that acts as a transcription factor to regulate
apoptosis, proliferation, and differentiation

. The clinical usefulness of 1α,25(OH) 2D3

139

and analogues has been limited by its tendency to promote hypercalcemia, an effect
related to its VDR-mediated role in calcium regulation. Another recent publication
detailing the anti-cancer effects of VD3 in murine models of basal cell carcinoma (BCC)
suggested that VD3 holds promise as a therapeutic agent in Hh -dependent cancers;
however, administration of VD3 resulted in significant VDR-mediated cellular effects

110

.

The development of VD3 analogues that exert their anti-cancer effects through
the Hh pathway inhibition would be less susceptible to hypercalcemic side-effects and
represent an improved class of vitamin D-based anti-cancer chemotherapeutics. The
studies described herein represent the first reported SAR studies for VD3 inhibition of Hh
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signaling. Employing A-Ring analogues with varying 3’ moieties, requirements for
optimal Hh inhibition and suitability of in vitro assay systems were probed.
2. Design and synthesis of A-Ring analogues
2.1 Overview

Scheme 1. Reaction conditions for synthesis of A-Ring analogues.
As the 3-(S)-hydroxyl of VD3 is the only non-carbon-hydrogen bond in the
structure, our initial efforts of studying the structure-activity relationships for VD3
inhibition of Hh signaling began with straightforward modifications at this position
(Scheme 1). These analogues were designed to probe the optimal configuration and
hydrogen bonding characteristics at C-3. Standard attempts to oxidize the hydroxyl to
the corresponding ketone (PDC, Dess-Martin periodinane) proved unsuccessful.
Conversion to keto VD3 (69) in modest yield was achieved under the more strenuous
Swern oxidation conditions

140

. Standard methylation provided the methoxy-VD3

derivative (70) in excellent yield. Mesylation of VD3, followed by substitution of the crude
3-(S)-OMs with sodium azide afforded the 3-(R)-N3 (25% yield over two steps).
Conversion to the corresponding amine (71) proceeded in modest yield (50%) via
standard Staudinger reduction conditions

141

. The inverted alcohol (72) was generated
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through Mitsunobu conditions optimized for the VD3 scaffold

142

. Subsequent conversion

of (72) to the 3-(S)-NH2 (73) proceeded in an analogues manner to that described above
for the inverted amine.
2.2 Experimental protocols
(Z)-3-((E)-2-((1R,7aR)-7a-methyl-1-((R)-6-methylheptan-2-yl)hexahydro-1H-inden
4(2H)-ylidene)ethylidene)-4-methylenecyclohexanone (69). A solution of DMSO (1.85
mL, 26.0 mmol) in anhydrous CH2Cl2 (12 mL) was added dropwise to a stirred solution
of oxalyl chloride (1.1 mL, 12.9 mmol) in CH2Cl2 (12 mL) at -78 °C under argon. This
solution was stirred at -78 °C for 30 min at which time a solution of vitamin D3 (1 g, 2.6
mmol) in CH2Cl2 (15 mL) was added. This mixture was stirred at -78 °C for 20 min,
triethylamine (9 mL, 65 mmol) was added, and the mixture was warmed to RT for 30
min. The mixture was diluted with CH2Cl2 (100 mL) and washed with H2O (100 mL). The
aqueous layer was removed, the organic layer washed with saturated NaCl (100 mL),
dried (Na2SO4), and concentrated. Chromatography (SiO 2, 3:1, CH2Cl2:Hex) afforded 69
as a clear oil in moderate yield (33%).1H NMR (CDCl 3, 500 MHz) δ 5.95 (s, 1H), 5.43 (s,
1H), 5.35 (s, 1H), 4.97 (t, J = 7.2 Hz, 1H), 3.18 (t, J = 7.5 Hz, 2H), 2.73 (m, J = 9.6, 5.4
Hz, 3H), 2.54 (m, J = 14.1, 7.7 Hz, 3H), 2.06 – 1.84 (m, 4H), 1.72 – 1.59 (m, 3H), 1.59 –
1.42 (m, 5H), 1.42 – 1.23 (m, 8H), 1.23 – 1.09 (m, 4H), 1.09 – 0.98 (m, 2H), 0.94 (d, J =
6.5 Hz, 3H), 0.89 (dd, J = 6.6, 2.3 Hz, 6H), 0.57 (s, 3H). 13C NMR (CDCl3, 125 MHz) δ
199.8, 157.9, 142.5, 141.7, 126.7, 115.0, 114.9, 56.5, 55.7, 45.3, 40.4, 39.5, 37.8, 36.2,
36.1, 32.0, 30.9, 28.7, 28.0, 27.6, 23.9, 23.3, 22.9, 22.6, 22.2, 18.9, 11.9. IR (film) ʋmax
2925, 2827, 2378, 1725, 1663, 1450, 1439, 1375, 1258, 1195, 750, 699 cm -1. ESIHRMS m/z calculated for C27H44O [M+H]+ 383.3308, found 383.3314.
(1S,Z)-3-((E)-2-((1R,7aR)-7a-methyl-1-((R)-6-methylheptan-2-yl)hexahydro-1H
inden-4(2H)-ylidene)ethylidene)-4-methylenecyclohexanol (70). A solution of vitamin
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D3 (50 mg, 0.13 mmol) and sodium hydride (4.1 mg, 0.17 mmol) in anhydrous THF (3
mL) was cooled to 0°C and stirred for 15 min. Methyl iodide (36 mg, 0.26 mmol) was
added dropwise and the solution warmed to 25°C and stirred for 12 hrs. The solution
was diluted with EtOAc (10 mL) and washed with H20 (10 mL). The aqueous layer was
removed, the organic layer washed with saturated NaCl (10 mL), dried (Na 2SO4), and
concentrated. Chromatography (SiO 2, 20:1, Hex:EtOAc) afforded 70 as a clear oil in
excellent yield (82%). 1H NMR (CDCl 3, 500 MHz) δ 6.25 (d, J = 11.2 Hz, 1H), 6.06 (d, J
= 11.2 Hz, 1H), 5.06 (s, 1H), 4.84 (s, 1H), 3.43 (m, 1H), 3.37 (s, 3H), 2.90 – 2.81 (m,
1H), 2.60 (d, J = 13.1, 1H), 2.47 – 2.38 (m, 1H), 2.31 (m, 1H), 2.19 – 2.10 (m, 1H), 2.05
– 0.99 (m, 24H), 0.89 (dd, J = 6.6, 2.2 Hz, 6H), 0.58 (s, 3H). 13C NMR (CDCl3, 125
MHz) δ 145.3, 141.7, 135.5, 121.8, 117.7, 112.2, 78.0, 56.6, 56.3, 55.8, 45.7, 42.4, 40.5,
39.4, 36.1 (2H), 32.2, 31.9, 28.0, 27.0, 27.6, 23.8, 23.5, 22.8, 22.5, 22.2, 18.8, 12.0. IR
(film) ʋmax 3007, 2950, 2847, 1722, 1467, 1442, 1388, 1255, 1098, 748, 699 cm -1. ESIHRMS m/z calculated for C28H47O [M+H]+ 399.3621, found 399.3646.
General synthetic procedure for generating 71 and 73. The general synthesis
of 71 and 73 followed a slight modification of the previously published procedure

141

.A

solution of vitamin D3 (1 g, 2.6 mmol) and triethylamine (1 g, 10.4 mmol) in CH2Cl2 (15
mL) was cooled to 0°C and stirred for 5 mins. Methanesulfonyl chloride (595 mg, 5.2
mmol) was added dropwise and the solution warmed to 25°C over 20 min. The CH2Cl2
was removed and the mixture redissolved in EtOAc (10 mL) and saturated sodium
bicarbonate (10 mL). The aqueous layer was removed, the organic layer was washed
with H20 (10 mL) and saturated NaCl (10 mL). The organic layer was dried (Na2SO4) and
concentrated. The resulting crude mesylate (1 g, 2.2 mmol) and sodium azide (1.43 g,
22 mmol) in anhydrous DMF (15 mL) was stirred at 60°C for 12 hr. The mixture was
diluted with EtOAc (50 mL) and H2O (50 mL). The aqueous layer was removed, the
organic layer washed with saturated NaCl (10 mL), dried (Na 2SO4), and concentrated.
44

Chromatography (SiO2, 1: 1, CH2Cl2: EtOAc) afforded the inverted azides as a yellow oil
in modest yield (25% over two steps). Azide (100 mg, 0.24 mmol), triphenylphosphine
(128 mg, 4.9 mmol), and H2O (43 μL, 2.4 mmol) were stirred in THF (10 mL) under
positive argon pressure at RT for 12 hr. The solution was concentrated and
chromatography (SiO 2, 20:1:0.1, CH2Cl2: MeOH, NH4OH) afforded the previously
described amines as a yellow oil in modest yield (50%).
3. Biological evaluation
3.1 Experimental protocols
RT-PCR protocol: Following treatment and incubation, RNA was extracted with
TRIZOL® Reagent following the manufacturer’s instructions. cDNA synthesis was
performed utilizing the High Capacity cDNA Reverse Transcription Kit (ABI) per the
manufacturer’s instructions on a BioRad MyCycler. Quantitative RT -PCR was performed
on an ABI 7500 system using the following Taqman Gene Expression Assays: h uman
GLI1,

Hs00171790_m1;

human

Cyp24A1,

Hs00167999_m1;

human

ActB,

Hs99999903_ml; mouse GLI1, Mm00494645_m1; mouse Cyp24A1, Mm00487244_m1;
mouse ActB, Mm00607939_s1. Relative gene expression levels were computed via the
ΔΔCt method using GraphPad Prism.
Anti-proliferation protocol: Cells (3000/well, 100 µL) were seeded in 96-well
plates and incubated overnight (37°C, 5% CO2). Cells were treated in triplicate with
DMSO, VD3, Cyc, or analogue at varying concentrations (1% DMSO final
concentration). Following 72-hr incubation, viable cells were measured using CellTiter
96® aqueous Non-Radioactive Cell Proliferation Assay (Promega) per the manufacturer’s
instructions. Data was analyzed using GraphPad Prism and IC 50 values represent mean
± SEM for at least three separate experiments.
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3.2 Results & discussion
The Hh inhibitory activity of VD3 and 69-73 was initially examined through downregulation of endogenous Gli1 mRNA in the Hh–dependent C3H10T1/2 cell line

46

. In

this well-studied model system, the Hh pathway is silent under normal growth conditions
and Gli1 expression is negligible. Incubation with oxysterols [20( S)- and 22(S)hydroxycholesterol, 5 µM each] activates the pathway and results in significant
(approximately 100-fold) up-regulation of Gli1 while co-administration with Hh pathway
inhibitors prevents Gli1 up-regulation. For these studies, VD3 and 69-73 were evaluated
at 5 µM and Gli1 mRNA expression levels were normalized to oxysterol controls (set as
100% expression). Several interesting SAR were observed from these assays (Table 1).
First, removal of the hydrogen in analogues 69 and 70 resulted in a moderate to
significant decrease in Hh inhibitory activity. In addition, both amine epimers, 71 and 73,
were 2-fold less active than VD3. Finally, inverting the stereochemistry at C-3 did not
have an appreciable effect on Hh inhibition, suggesting the S-configuration of natural
VD3 is not required for activity.
Table 1. In vitro activity of VD3 A-ring analogues.
6.93 ±1.93

Anti-proliferation
b
IC50 (µM)
22.5 ± 0.5

VDR
Binding
----

3-(S)-OH

31.7 ± 0.7

29.7 ± 3.1

>100µM

69

3-keto

50.1 ± 6.4

50.6 ± 1.8

>100µM

70

3-(S)-OMe

72.2 ± 11

54.2 ± 6.2

>100µM

71

3-(R)-NH2

68.0 ± 7.0

12.3 ± 0.5

>100µM

72

3-(R)-OH

25.0 ± 6.0

39.2 ± 1.5

>100µM

73

3-(S)-NH2

62.7 ± 2.7

12.3 ± 0.1

>100µM

Analogue

3-moiety

Relative Gli1 mRNA (%)

Cyc

----

VD3

a

a

Relative Gli1 mRNA levels in C3H10T1/2 w hen oxysterol treatment is equivalent to 100%.
IC50 values measured in U87MG cells (MTS assay).

b

In addition to evaluating the Hh inhibitory activity of VD3 and analogues, we
sought to measure their anti-proliferative activities in human cancer cells. Recent studies
46

have suggested that the in vivo tumor microenvironment is required for proper Hh
signaling and that cultured cancer cells may not function as an appropriate model
system

12

. Nevertheless, Cyc treatment was previously shown to result in Gli1 down -

regulation in the human glioblastoma cell line U87MG; therefore, we evaluated VD3 and
analogues in this cellular model

143

. Interestingly, the two most active analogues in this

assay were 71 and 73, the 3-(R)- and 3-(S)-amines (IC50s = 12.3 ± 0.1 and 12.3 ± 0.1,
respectively). These results were in direct contrast with the Hh inhibitory activity of these
compounds. The other compounds demonstrated modest anti-proliferation with IC50
values approximately 3-fold higher than 71 and 73.
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Figure 2. Relative Gli1 mRNA expression in U87MG cells.
(A) 5 µM treatment at 24 hr (B) Time-dependent Gli1 regulation with 10 µM compound.
The further analysis of VD3 and analogues included evaluating their ability to
down-regulate Gli1 in U87MG cells. At 5 µM, none of the compounds evaluated
significantly down-regulated Gli1 expression after 24 hrs (Figure 2A). As previous
studies that demonstrated Cyc inhibits Hh signaling in U87MG cells measured Gli1
down-regulation following 4 hr incubation at 10 µM of the natural product, we evaluated
each Hh inhibitor at this increased concentration and varying time points (Figure 2B)

143

.

Under these conditions, none of the compounds tested demonstrated significant Gli1
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down-regulation in this cell line. In fact, Cyc treatment resulted in a slight increase in Gli1
expression levels at 8 hr.
Based on these conflicting results and our ultimate goal of developing VD3
analogues that specifically target Smo and the Hh pathway, we evaluated each
compound for its ability to regulate VDR signaling. VD3 and analogues were explored for
their ability to bind VDR. For this assay, we utilized the PolarScreen™ VDR Competitor
Assay, Red (Invitrogen) per the manufacturer’s instructions. This assay is a fluorescence
polarization-based competition assay that has been optimized for high -throughput
applications and contains all the required components (including full length human VDR
and a proprietary tight-binding fluorescent VDR ligand). Neither VD3 nor the A-ring
analogues exhibited VDR binding at concentrations up to 100 µM, suggesting these
compounds do not exhibit their biological activity through direct binding interactions with
VDR (Table 1).

Figure 3. Vitamin D metabolic pathway.
Our next step towards understanding the cellular mechanisms responsible for the
anti-proliferative activity of VD3 and 69-73 in U87MG cells was to evaluate their ability to
activate VDR in cell culture. Primarily, VD3 is metabolized in liver and kidney by various
Cyp450 enzymes to yield 25(OH)D3 and 1α,25(OH) 2D3 (Figure 3), forms of vitamin D
which bind and activate VDR. Recent evidence has shown that various types of human
cancers express increased levels of these metabolic enzymes
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144-147

. While it remains

unclear whether the over-expression of these enzymes plays a role in the proliferation of
human cancers, their presence outside the liver and kidney suggests that the possible
metabolic transformation of VD3 and analogues in cancer cells may result in structures
which activate VDR signaling

148

. With respect to VDR regulation, Cyp24A1 is

responsible for converting 1α,25(OH) 2D3 into the physiologically inactive calcitroic acid.
Cyp24A1 is elevated in response to VDR activation and serves as a natural feedback
mechanism to regulate VDR signaling. For this reason, induction of Cyp24A1 is
commonly used to monitor cellular activation of the VDR signaling. Incubation of U87MG
cells with VD3 resulted in significant up-regulation of Cyp24A1 (~5-fold, Table 2). In
addition, the VD3-epimer 72 demonstrated Cyp24A1 up-regulation comparable to VD3.
Each amine exhibited modest VDR activation, while neither keto- nor methoxy-VD3 had
a significant effect. In order to determine whether these effects were cell type
dependent, we explored Cyp24A1 up-regulation in HT-29 cells, a colon cancer cell line
known to produce a robust and reproducible Cyp24A1 response to 1 α,25(OH) 2D3
administration 149, 150. VD3, 1α,25(OH) 2D3 (0.1 µM), and 72 demonstrated significant upregulation of Cyp24A1 in HT-29 cells. A recent study reported a modest increase in
Cyp27A1 and Cyp27B1 expression upon administration of VD3 in HT-29 cells 151. In this
same study, significant up-regulation of Cyp24A1 following VD3 treatment was delayed
compared to 1α,25(OH) 2D3

(24 hr and 4 hr, respectively), suggesting cellular

conversion of VD3 to a more active form is necessary for VDR activation. By contrast,
Cyc had no effects on Cyp24A1 in either cell line, confirming this effect as specific to the
VD3 scaffold and not a general response related to Hh inhibition. Finally, we studied the
ability of each compound to up-regulate Cyp24A1 in the C3H10T1/2 cell model. Similar
to the results obtained in HT-29 cells, both VD3 and 72 resulted in significant Cyp24A1
up-regulation (Table 2). Of note, these results do not explain the anti-cancer activity for
amines 71 and 73. These two analogues were the most active in the anti-proliferative
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assays; however, they are poor inhibitors of Hh signaling and do not activate VDR in
cultured cells, suggesting their activity may be mediated by an as yet unidentified ce llular
signaling mechanism.
Table 2. Up-regulation of Cyp24A1 mRNA expression by VD3 and analogues.
a

Analogue

U87MG

HT-29

C3H10T1/2

Cyc
VD3

1.6 ± 0.1
4.9 ± 1.1

0.9 ± 0.1
1063 ± 83

0.99 ± 0.1
5786 ± 190

69
70

1.3 ± 0.02
1.0 ± 0.1

0.9 ± 0.1
4.2 ± 0.1

130 ± 33
1.1 ± 0.1

71
72

3.3 ± 0.4
6.9 ± 1.2

6.1 ± 0.2
1654 ± 48

6.3 ± 2.2
1444 ± 241

73
1α,25(OH) 2D3

3.5 ± 0.3
----

6.4 ± 0.1
14160 ± 691

13.0 ± 3.6
27890 ± 2774

b

a

All compounds except 1α,25(OH)2D3 (0.1 µM) evaluated at 5 µM in C3H10T1/2 & 10 µM in HT-29 &
U87MG
b
Values represent Cyp24A1 mRNA expression level in cultured cells w hen DMSO set as 1.0.
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Figure 4. Relative Cyp24A1 mRNA levels in C3H10T1/2 cells.
VD3 (A), 25(OH)D3 (B), and 1α,25(OH) 2D3 (C) treatment (24hr).
DMSO w as set as 1.0 and mRNA expression levels for treatments w ere calculated accordingly [p<0.0001].
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The data for VD3 supports our hypothesis that its metabolism in cultured cancer
cells results in a form that more readily activates VDR; however, these results also
provide another source of potential confusion regarding VDR/Hh signaling. Recent
studies exploring the relationships between VDR signaling and the Hh pathway have
suggested that 1α,25(OH) 2D3 may directly regulate Hh signaling

152

. It is unclear

whether these modulatory effects are mediated through direct inhibition of Hh signaling
or as a downstream effect of VDR activation. In addition, minimal studies detailing the
effects of 1α,25(OH) 2D3 in C3H10T1/2 cells have been reported. For these reasons, we
sought to evaluate the dose-dependent effects on Hh and VDR signaling of VD3,
25(OH) 2D3 and 1α,25(OH) 2D3 in this cell line (Figure 4). Not surprisingly, each vitamin D
compound significantly up-regulated Cyp24A1 in a dose-dependent fashion. Of note, the
lowest concentration of VD3 evaluated (0.5 µM) did not activate VDR signaling, while
both 25(OH) 2D3 and 1α,25(OH) 2D3 maintained robust Cyp24A1 up-regulation; lending
further support to the hypothesis that these VD3 metabolites, and not VD3 itself, mediate
the VDR response seen upon VD3 administration. In addition, both 25(OH) 2D3 and
1α,25(OH) 2D3 significantly reduced GLI1 expression levels in this cell line.
4. Conclusion
Taken together, these results provide a better understanding of the necessary
requirements for developing VD3 analogues as selective Hh pathway inhibitors. First,
not only can VD3 analogues not directly interact with VDR, modifications to the scaffold
must also yield structures that are not substrates for Cyp27A1 and Cyp2R1, enzymes
that catalyze the metabolism of VD3 to 25(OH)2D3. Second, while both 25(OH)2D3 and
1α,25(OH)2D3 inhibit Hh signaling, they produce a robust VDR response in multiple cell
lines and do not represent selective scaffolds for the development of Hh pathway
inhibitors. Finally, as described above, there is no correlation between Hh inhibition in
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C3H10T1/2 cells and Gli1 down-regulation in cultured epithelial cancer cells, supporting
the recent findings that the in vivo tumor microenvironment is required for proper Hh
signaling in human cancer.
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CHAPTER III: Design, Synthesis and Evaluation of Hybrid Vitamin D3 Side Chain
Analogues as Hedgehog Pathway Inhibitors

53

1. Introduction
Previous studies undertaken in our lab revealed that VD3 mediated inhibition of
Hh signaling in vitro is modest (IC50 = 4.1μM) and non-selective due to its ability to
concurrently activate canonical VDR signaling

108, 113

. Thereafter, a medicinal chemistry

approach was undertaken to design analogues of VD3 that selectively target Hh
signaling. Initial attempts with analogues prepared by simple modifications of the 3’hydroxyl functionality of the A-ring proved inadequate 108. Next, as a part of our ongoing
SAR studies to elucidate the pharmacophore of VD3 necessary for selective inhibition of
Hh signaling, we adopted a deconstructive approach of studying analogues arising from
each region of VD3 (Figure 1)

111

. The key observations of this study were that the

truncated side chain analogues of VD3, 74, Inhoffen Lythgoe diol, 75, along with the
‘southern’ fragment of VD3, 76, showed a considerable loss of activity. However,
analogues with intact ‘northern’ regions of VD3 and VD2, 77 and 78, retained Hh
inhibitory activity comparable to VD3 albeit in a more selective fashion (Table 1).
Therefore, probing the structural requirements of the CD-ring side chain region was the
next warranted step. Studies described in this chapter were aimed at unraveling the
optimum requirements for length and nature of VD3 side chain for potent and selective
Hh inhibitory activity.

Figure 1. Structures of truncated VD3 analogues.
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Table 1. Gli1 inhibitory activity and selectivity of truncated VD3 analogues.
a

Analogue

Relative Gli1 mRNA (%)

Relative Cyp24A1 mRNA

VD3

35.7 ± 0.3

8336 ± 38

74

80.0 ± 10.4

1354 ± 61

75

87.6 ± 1.2

4.1 ± 0.7

76

46.4 ±3.5

3.6 ± 0.5

77

80.9 ± 2.1

2.0 ± 0.2

78

32.1 ± 6.3

2.3 ± 1.2

b

a

Relative Gli1 mRNA levels in C3H10T1/2 w hen oxysterol treatment is equivalent to 100%.
Values represent Cyp24A1 mRNA expression in cultured cells relative to DMSO (1.0).

b

Initial attempts to prepare side chain derivatives proceeded with sulfur dioxide
protection of the VD2 triene and protection of the 3’ hydroxyl group as the silyl ether,
followed by selective ozonolysis/reduction of the side chain olefin to provide T ESprotected trans-VD3 alcohol 82 (Scheme 1) 153. The next steps included tosylation of the
resultant primary hydroxyl group and removal of the triene protecting group yie lding the
trans-VD3 derivative 84 153, 154. Subsequent photoisomerism led to precursor 85 required
for the alkylation reaction via displacement of the primary tosylate using various
commercially available Grignard reagents

153, 155

. Finally deprotection of the 3’-hydroxyl

group afforded analogues with modified side chains 86. This initial scheme to prepare
VD3 analogues with side chain modifications proved challenging as several attempts to
displace the tosyl functionality using a Grignard’s reagent either failed or proceeded in
extremely low yields (0% - 5%). Additionally, the inherent instability of the conjugated
triene system of VD3 in solution due to thermal equilibrium between VD3 and pre -VD3
via a [1, 7]-sigmatropic hydrogen shift, posed general complications during synthetic
manipulations of this structure 156. Further biological evaluation of analogue 86 could not
be carried out due to lack of necessary amounts of pure product required for complete
chemical characterization and sample preparation for dosing cells.
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Scheme 1. Synthetic route to VD3 side chain analogues.
In concurrent studies, the ‘northern’ region of VD3, also known as Grundmann’s
alcohol (77), was found to be equipotent to the parent VD3 scaffold (IC 50 values = 3.1
and 4.1 µM respectively)

111, 113

. Based on this finding, subsequent series of VD3

analogues designed to incorporate an aromatic A-ring isostere that maintains the
approximate steric and hydrophobic features of the natural aliphatic A-ring into the secosteroid scaffold identified compound 87 as a selective Hh inhibitor with enhanced activity
(IC50 = 0.74 µM) (Figure 2)

113

.

Following the identification of improved Hh inhibitory

scaffold 87, we directed our efforts to incorporate the side chain modifications on this
revised core structure. With this revision in design strategy, we aimed to fulfill analogue
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optimization for enhanced potency and selectivity along with affording relative efficiency
and ease in accessing hybrid side chain analogues.

Figure 2. Development of hybrid VD3 as selective and potent Hh inhibitor.
2. Synthesis of hybrid side chain analogues of VD3
2.1 Overview
2.1.1 Route 1
Complete ozonolysis of VD2 and subsequent reduction of the resultant ozonide
in a one-pot reaction generated the previously characterized Inhoffen Lythgoe diol, 75
(Scheme 2) 157. The next step of preferential tosylation of the primary hydroxyl group in
presence of another slightly hindered secondary hydroxyl group proceeded with modest
yields leading to the preparation of key CD ring intermediate ( 88, Scheme 2)

158

. For the

synthesis of the Ring-A aromatic mimic two consecutive protection/deprotection steps
were carried out to prepare the carboxylate intermediate ( 91, Scheme 2) 159, 160. With the
necessary precursors in hand, the next step of esterification to prepare intermediate ( 92)
proceeded with modest yields (Scheme 3)

113

. Syntheses of two linear (93, 94), one

branched alkyl (95) and one aromatic (96) side chain derivative were accomplished via
displacement of the tosyl functional group from intermediate ( 92) using appropriate alkyl
nucleophiles followed by a final deprotection step (Scheme 3). However, it became
necessary to determine an alternate method due to the low yields and inconsistent
reproducibility of the tosyl displacement step. Therefore, we sought to identify a viable
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route to prepare additional analogues in an efficient manner using the current building
blocks and available infrastructure.

Scheme 2. Route 1: Synthesis of CD-ring and A-ring precursor.

Scheme 3. Route 1: Preparation of hybrid side chain analogues.
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2.1.2 Route 2
In this alternate route (Scheme 4), displacement of the tosyl moiety by relevant
alkyl nucleophiles was carried out on intermediate (88) prior to the esterification step

155

.

After installation of the necessary side chains on the CD-ring fragment to generate
intermediate (97), previously described methods for esterification with intermediate ( 91)
and unmasking of the 3’ hydroxyl group of the aromatic A-ring mimic were carried out
with improved yields.

In this manner, a total of seven additional linear as well as

branched alkyl chain analogues (98 – 104) were synthesized.

Scheme 4. Route 2: Preparation of hybrid side chain analogues.
2.1.3 Route 3
The preparation of additional hybrid VD3 side chain analogues was undertaken
by adopting relevant modifications of the previously described routes. For instance,
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naturally occurring unsaturated side chain precursor ( 78) was obtained from VD2 by
oxidative cleavage of the VD2 triol (Scheme 5)

111

. By varying the nature of protecting

groups used for masking A-ring phenolic moiety and hence the subsequent deprotection
reactions required, two derivatives containing VD2-like side chains were accessible from
78 (Scheme 6). First, employing benzyl protected intermediate 106 in the esterification
reaction followed by global deprotection and reduction afforded analogue 109 with
relative ease. Alternately, coupling to A-ring mimic precursor 91 containing the
methoxymethyl functionality led to the preparation of analogue 111 with an unsaturated
side chain. Next, utilizing trimethylsilyl ether to mask the primary hydroxyl moiety of the
Inhoffen Lythgoe diol, intermediate 107 was synthesized in the presence of a catalytic
amount of DMAP

161

. Esterification of this intermediate succeeded by one-step removal

of both protecting functional groups produced non-hydrocarbon side chain containing
analogue 113 (Scheme 5 and 6).

Scheme 5. Route 3: synthesis of CD-ring and A-ring precursor.
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Scheme 6. Route 3: Access additional hybrid side chain analogues.
2.1.4 Synthetic strategy
The displacement of the tosyl functional group with a carbon based nucleophile
obtained from relevant Grignard reagents represents the key transformation leading to
the installation of various side arms on the hybrid VD3 scaffold. Initial attempt s to carry
out this reaction on relatively bulkier molecules such as intermediate 85 (Scheme 1) or
intermediate 92 (Scheme 3) proved inadequate and inefficient. Not only were the
reaction yields extremely poor (5%-10%), the reactions rarely proceeded to completion.
Furthermore, methodical investigation of the effects of altering reaction parameters
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including reaction time, temperature, solvent and copper catalyst did not offer
reasonable improvement.

Figure 3. Comparison of intermediate structures during Ts displacement reaction.
Thereafter, the synthetic strategy was modified based on the hypothesis that less
bulky substrates may facilitate effective completion of the rate determining step of
complex formation with the copper catalyst (Figure 3). Guided by a previous literature
report detailing successful displacement of the tosyl moiety from tosylated Inhofen
Lythgoe diol 88 with Grignard reagents, a revised strategy (Route 2, Scheme 4) was
adopted 162. Although this shift in strategy lengthened the synthetic route to access the
analogues, it afforded reaction reproducibility and improved yields.
2.2 Experimental protocols
Preparation of tosylated MOM-ester (92): Tosylated Inhoffen Lythgoe diol (88)
(0.2

g,

0.55

mmol),

dicyclohexylcarbodiimide
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(0.34

g,

1.65

mmol),

and

dimethylaminopyridine (0.2 g, 1.64 mmol) were dissolved in anhydrous CH2Cl2 (6-8 ml)
in an oven-dried round bottom flask. Carboxylic acid (91) (0.3 g, 1.65 mmol) was added
at 0o C, the reaction mixture was allowed to warm to RT and stirred for 12 h. The
reaction mixture was diluted with CH2Cl2 (30 ml), washed with 0.1N HCl and brine, dried
over Na2SO4 and concentrated under reduced pressure. The crude mixture was purif ied
using column chromatography (SiO 2, 5-25% EtOAc in hexanes) to yield product as clear
oil in 40% yield.
General procedure for Tosyl group displacement: Commercially purchased
Grignard reagents (5 eq.) were added to an oven-dried round bottom flask containing
CuI (1.6 eq.) in anhydrous THF (3-5 ml) under argon and stirred for 0.5 h at 0 oC. (85) (1
eq.) or (92) (1 eq.) or (88) (1 eq.) dissolved in anhydrous THF (1 ml) was added to the
reaction mixture and stirred for 1 h at 0 oC. The reaction was quenched by addition of
water, extracted with EtOAc (3X), washed with 0.1N HCl (3X), dried over Na 2SO4 and
concentrated under reduced pressure. The crude mixture was purified using column
chromatography (SiO 2, 0-20% EtOAc in hexanes) to yield products as clear oils in 1040% yield.
General procedure for removal of methoxymethyl (MOM) protecting group:
To a solution of MOM-protected ester intermediate (20-25 mg, 1 eq.) in DCM (2 ml),
excess of trifluoroacetic acid (10 eq.) was added. The reaction mixture was stirred a t RT
and reaction progress was monitored by thin layer chromatography. Upon completion,
the reaction was neutralized using saturated Na 2CO3 and washed with DCM. The
combined organic layer was dried over Na 2SO4, concentrated under reduced pressure
and purified using column chromatography (SiO 2, 0-15% EtOAc in hexanes) to yield
products as clear oils in 65% yield.
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General procedure for esterification: (97), (78), or (107) (1 eq.),
dicyclohexylcarbodiimide (3 eq.), and dimethylaminopyridine (3 eq.) were dissol ved in
anhydrous DCM (2-4 ml) in an oven-dried round bottom flask. Carboxylic acid (91) (3
eq.) dissolved in DCM was added at 0 oC, the reaction mixture was allowed to warm to
RT and stirred for 12 h. The reaction mixture was diluted with DCM (3x), washed with
0.1N HCl and brine, dried over Na 2SO4 and concentrated under reduced pressure. The
crude mixture was purified using column chromatography (SiO 2, 5-25% EtOAc in
hexanes) to yield products as clear oils in 50-70% yield.
Preparation of benzyl protected methyl ester (105): To a stirred solution of 3phenolic methyl ester 89 (1eq., 6.5 mmol) in acetone (30 mL), was added potassium
carbonate (anhydrous, 6 eq., 39 mmoL) followed by benzyl bromide (1.2 eq., 7.9 mmol).
The reaction mixture was refluxed until methyl ester was consumed (6h). The mixture
was filtered over a celite pad, washed with EtOAC (30 mL), and concentrated. The crude
residue was purified by column chromatography on silica gel (5% EtOAC in hexanes) to
afford pure product as a clear oil in excellent yield (85%).
Preparation of benzyl protected 3’ hydroxybenzoic acid (106): To a stirred
solution of ester (105) (3.7 mmol) in THF (30 mL) was added potassium hydroxide (aq.,
20%; 20 mL). The reaction mixture was stirred at room temperature for 12 hr at which
time it was neutralized with portion-wise additions of 3N HCl and then the pH was
reduced to ~1 using 1N HCl. The aqueous mixture was washed with EtOAc (3X100 mL).
The combined organic fractions were dried (Na 2SO4), filtered, and concentrated under
reduced pressure. The crude residue was purified by column chromatography on silica
gel (30-50% EtOAC in hexanes) to afford pure productas a white solid in good yield
(70%).
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Preparation of analogue 109: To a solution of benzyl-protected ester 108 (0.15
mmoL) in MeOH:THF (2:1, 6 mL) was added palladium hydroxide (10% on carbon; 10
mg). The mixture was sealed with a rubber septum, sequentially purged with argon and
hydrogen, and stirred under positive hydrogen pressure (1 atm) at RT for 18 h. The
mixture was ﬁltered through a Celite pad, rinsed with EtOAC (10 mL) and concentrated
under reduced pressure. The crude residue was puriﬁed using column chromatography
(SiO2, 10−40% EtOAc in hexanes) to yield 109 in 75% yield.
Preparation of TMS protected Inhoffen Lythgoe diol (107): To a solution of
Inhoffen Lythgoe diol 75 (0.2 g, 0.9 mmol) in anhydrous DCM (10 ml), triethylamine
(0.15 ml, 1.1 mmol), dimethylaminopyridine (0.004 g, 0.04 mmol) and TMSCl (0.127 ml,
0.99 mmol) were added and stirred overnight. The reaction mixture was diluted with
DCM, washed with water, dried over Na 2SO4 and concentrated under reduced pressure.
Purification using column chromatography (SiO 2, EtOAc in hexanes) yielded pure
product as clear oil in 49% yield.
(1R,3aR,4S,7aR)-1-isopropyl-7a-methyloctahydro-1H-inden-4-yl 3-hydroxybenzoate (93): 1H NMR (500 MHz, CDCl3) δ 7.65 (m, J = 7.8, 1.2 Hz, 1H), 7.58 (m, J = 2.6, 1.2
Hz, 1H), 7.35 (m, J = 7.9, 2.2 Hz, 1H), 7.07 (m, J = 8.1, 2.4, 1.0 Hz, 1H), 5.42 (m, J = 2.7
Hz, 1H), 5.36 (s, 1H), 2.13 – 2.04 (m, 2H), 2.01 (dd, J = 14.5, 3.8 Hz, 1H), 1.84 (m, J =
21.5, 18.5, 9.3, 5.3 Hz, 3H), 1.56 (m, J = 20.7, 14.0, 10.9, 7.3, 3.6 Hz, 7H), 1.50 – 1.38
(m, 1H), 1.36 – 1.30 (m, 1H), 1.26 – 1.18 (m, 1H), 1.06 (d, J = 2.2 Hz, 4H), 0.98 (dd, J =
6.5, 2.2 Hz, 3H), 0.88 (dd, J = 6.6, 2.2 Hz, 3H).

13

C NMR (126 MHz, CDCl3) δ 166.5,

155.8, 132.4, 129.7, 122.0, 119.9, 116.3, 72.6, 58.5, 51.6, 41.9, 39.8, 30.7, 30.5, 29.7,
27.3, 23.0, 22.7, 22.4, 18.0, 13.7. IR (film) ʋ max 3430 (br s), 2956, 2939, 2868, 2858,
1700, 1684, 1601, 1589, 1294, 1217, 1160, 1110, 946, 756, 680, 669. DART -HRMS:
m/z calculated for C20H28O3NH4: 334.2382 [M+NH4]+. Found: 334.2373.
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(1R,3aR,4S,7aR)-7a-methyl-1-((R)-pentan-2-yl)octahydro-1H-inden-4-yl 3-hydroxybenzoate (94): 1H NMR (500 MHz, CDCl3) δ 7.65 (m, J = 7.6, 2.9, 1.5 Hz, 1H), 7.59 (p, J
= 1.9 Hz, 1H), 7.34 (m, J = 7.9, 2.0 Hz, 1H), 7.11 – 7.05 (m, 1H), 5.51 (s, 1H), 5.45 –
5.40 (m, 1H), 2.13 – 2.06 (m, 1H), 1.92 – 1.77 (m, 2H), 2.01 (m, J = 12.9, 5.1, 2.7 Hz,
1H), 1.69 – 1.50 (m, 5H), 1.50 – 1.34 (m, 3H), 1.29 (t, J = 2.3 Hz, 3H), 1.21 – 1.11 (m,
1H), 1.06 (p, J = 2.7 Hz, 4H), 0.95 (m, J = 6.5, 2.1 Hz, 3H), 0.93 – 0.87 (m, 3H).
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C

NMR (126 MHz, CDCl3) δ 166.6, 155.9, 132.5, 129.8, 122.1, 120.1, 116.5, 72.8, 56.7,
51.8, 42.1, 40.1, 38.3, 35.4, 30.7, 29.9, 27.3, 22.9, 19.4, 18.8, 18.2, 13.8. IR (film) ʋ max
3400 (br s), 2976, 2947, 2867, 2866, 1684, 1600, 1579, 1296, 1215, 1145, 1110, 946,
756, 680, 659. DART-HRMS: m/z calculated for C22H32O3NH4: 362.2695 [M+NH4]+.
Found: 362.2714.
(1R,3aR,4S,7aR)-7a-methyl-1-((R)-5-methylhexan-2-yl)octahydro-1H-inden-4-yl 3hydroxybenzoate (95): 1H NMR (500 MHz, CDCl3) δ 7.65 (d, J = 7.5 Hz, 1H), 7.59 (d, J
= 6.8 Hz, 1H), 7.35 (t, J = 8.0 Hz, 1H), 7.13 – 7.03 (m, 1H), 5.42 (m, J = 4.1, 2.2 Hz, 1H),
2.08 (m, J = 11.3, 3.9 Hz, 1H), 2.05 – 1.97 (m, 1H), 1.93 – 1.71 (m, 2H), 1.56 (m, J =
18.9, 12.5, 8.9, 4.5 Hz, 4H), 1.49 – 1.30 (m, 6H), 1.28 – 1.09 (m, 4H), 1.05 (s, 3H), 0.96
(d, J = 13.2, 6.2 Hz, 3H), 0.91 (dd, J = 6.6, 1.9 Hz, 6H).

C NMR (126 MHz, CDCl3) δ

13

166.3, 155.7, 132.4, 129.7, 122.0, 119.9, 116.3, 72.6, 58.5, 51.6, 41.9, 39.8, 35.5, 31.9,
30.9, 30.7, 30.5, 29.7, 27.3, 23.0, 22.7, 22.4, 18.0, 13.7. IR (film) ʋ max 3385 (br s), 3019,
2951, 2935, 2868, 1689, 1599, 1589, 1466, 1453, 1366, 1344, 1295, 1215, 1157, 1106,
1075, 1062, 982, 946, 886, 755, 680, 668. DART -HRMS: m/z calculated for
C24H36O3NH4: 391.2848 [M+NH4]+. Found: 391.2869.

(1R,3aR,4S,7aR)-7a-methyl-1-((R)-4-phenylbutan-2-yl)octahydro-1H-inden-4yl 3-hydroxybenzoate (96): 1H NMR (500 MHz, CDCl3) δ 7.64 (d, J = 7.6 Hz, 1H),
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7.60 – 7.57 (m, 1H), 7.33 (dd, J = 21.9, 7.9 Hz, 3H), 7.22 – 7.17 (m, 3H), 7.08 (dd, J =
8.1, 2.6 Hz, 1H), 5.57 (s, 1H), 5.42 (q, J = 2.7 Hz, 1H), 2.73 (m, J = 13.2, 11.2, 4.8 Hz,
1H), 2.50 (m, J = 13.4, 10.8, 6.0 Hz, 1H), 2.11 (m, J = 12.7, 3.5 Hz, 1H), 2.02 (m, J =
14.1, 2.5 Hz, 1H), 1.96 – 1.71 (m, 4H), 1.67 (q, J = 4.1 Hz, 1H), 1.64 – 1.45 (m, 4H),
1.44 – 1.33 (m, 1H), 1.29 (s, 2H), 1.24 (d, J = 7.3 Hz, 1H), 1.07 (d, J = 6.6 Hz, 3H), 1.05
(s, 3H).

C NMR (126 MHz, CDCl3) δ 166.4, 155.8, 143.3, 132.3, 129.7, 128.4, 128.3,
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125.5, 121.9, 120.0, 116.3, 72.6, 56.2, 51.6, 42.0, 40.0, 37.9, 35.3, 32.5, 30.5, 27.0,
22.7, 18.6, 18.0, 13.6. IR (film) ʋmax 3170, 2949, 2917, 2849, 1692, 1496, 1484, 1453,
1250, 1224, 756. DART-HRMS: m/z calculated for C27H33O3: 405.2430 [M-H]+. Found:
405.2437; calculated for C27H34O3NH4: 424.2852, [M+NH4]+. Found: 424.2869.
(1R,3aR,4S,7aR)-1-((R)-sec-butyl)-7a-methyloctahydro-1H-inden-4-yl 3-hydroxybenzoate (98): 1H NMR (500 MHz, CDCl3) δ 7.65 (m, J = 7.7, 1.2 Hz, 1H), 7.61 (dd, J =
2.6, 1.5 Hz, 1H), 7.38 – 7.31 (m, 1H), 7.08 (m, J = 8.1, 2.5, 1.0 Hz, 1H), 5.57 (s, 1H),
5.43 (q, J = 2.8 Hz, 1H), 2.12 – 2.06 (m, 1H), 2.05 – 1.98 (m, 1H), 1.91 – 1.77 (m, 2H),
1.64 – 1.43 (m, 6H), 1.41 – 1.30 (m, 2H), 1.25 (m, J = 7.9, 4.7, 2.6 Hz, 1H), 1.21 – 1.07
(m, 2H), 1.06 (s, 3H), 0.95 (d, J = 6.4 Hz, 3H), 0.89 – 0.83 (m, 3H).
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C NMR (126 MHz,

CDCl3) δ 166.7, 156.0, 132.5, 129.9, 122.1, 120.2, 116.6, 72.9, 56.1, 51.8, 42.1, 40.1,
36.8, 30.7, 29.9, 28.3, 27.1, 22.2, 18.2, 18.2, 13.8. IR (film) ʋ max 3329 (br s), 3146, 3017,
2950, 2931, 2867, 1671, 1613, 1584, 1485, 1466, 1250, 1208, 1137, 1088, 1 061, 1032,
937, 917, 755, 702, 666. DART-HRMS: m/z calculated for C21H30O3NH4: 348.2539
[M+NH4]+. Found: 348.2564.
(1R,3aR,4S,7aR)-1-((R)-hexan-2-yl)-7a-methyloctahydro-1H-inden-4-yl 3-hydroxybenzoate (99): 1H NMR (500 MHz, CDCl3) δ 7.65 (d, J = 7.6 Hz, 1H), 7.58 (d, J = 2.6
Hz, 1H), 7.39 – 7.31 (m, 1H), 7.12 – 7.04 (m, 1H), 5.43 (s, 1H), 5.41 – 5.31 (m, 1H), 2.14
– 2.05 (m, 1H), 2.05 – 1.96 (m, 1H), 1.92 – 1.75 (m, 2H), 1.74 – 1.51 (m, 5H), 1.51 –
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1.30 (m, 4H), 1.29 – 1.08 (m, 9H), 1.06 (s, 3H), 1.02 – 0.96 (m, 3H), 0.89 (t, J = 3.9 Hz,
4H). 13C NMR (126 MHz, CDCl3) δ 166.4, 155.9, 132.5, 129.9, 122.2, 120.1, 116.5, 72.8,
58.7, 51.8, 42.1, 40.0, 30.9, 30.7, 29.9, 27.5, 23.2, 22.9, 22.6, 22.2, 18.2, 14.2, 13.9. IR
(film) ʋ max 3305 (br s), 3234, 2951, 2931, 2867, 2775, 1610, 1584, 1485, 1466, 1364,
1346, 1250, 1208, 1137, 1086, 1062, 1032, 937, 917, 755, 715, 656. DART -HRMS: m/z
calculated for C23H34O3NH4: 376.2887 [M+NH4]+. Found: 376.2891
(1R,3aR,4S,7aR)-1-((R)-heptan-2-yl)-7a-methyloctahydro-1H-inden-4-yl 3-hydroxybenzoate (100): 1H NMR (500 MHz, CDCl3) δ 7.65 (dd, J = 7.5, 1.6 Hz, 2H), 7.35 (t, J =
8.0 Hz, 1H), 7.13 – 7.03 (m, 1H), 5.79 (s, 1H), 5.42 (dd, J = 4.1, 2.2 Hz, 1H), 2.08 (m, J
= 11.3, 3.9 Hz, 1H), 2.05 – 1.97 (m, 1H), 1.93 – 1.71 (m, 2H), 1.56 (m, J = 18.9, 12.5,
8.9, 4.5 Hz, 4H), 1.49 – 1.30 (m, 6H), 1.28 – 1.09 (m, 7H), 1.05 (s, 3H), 0.96 (dd, J =
13.2, 6.2 Hz, 3H), 0.91 (t, J = 7.1 Hz, 3H).

C NMR (126 MHz, CDCl3) δ 166.7, 156.0,
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132.4, 129.9, 122.1, 120.2, 116.6, 72.9, 56.6, 51.8, 42.1, 40.1, 35.8, 35.6, 32.5, 30.7,
27.2, 25.9, 22.9, 22.9, 18.8, 18.2, 14.3, 13.8. IR (film) ʋ max 3375 (br s), 3138, 3011,
2951, 2931, 2867, 1613, 1584, 1485, 1466, 1364, 1346, 1250, 1208, 1137, 1086, 1062,
1032, 937, 917, 755, 704, 657. DART-HRMS: m/z calculated for C24H36O3NH4: 390.3008
[M+NH4]+. Found: 390.3045.
(1R,3aR,4S,7aR)-7a-methyl-1-((R)-4-methylpentan-2-yl)octahydro-1H-inden-4-yl 3hydroxybenzoate (101): 1H NMR (500 MHz, CDCl3) δ 7.65 (d, J = 7.5 Hz, 1H), 7.59 (d,
J = 6.8 Hz, 1H), 7.35 (q, J = 7.9, 7.3 Hz, 1H), 7.07 (d, J = 7.8 Hz, 1H), 5.42 (s, 2H), 2.17
– 2.08 (m, 1H), 2.02 (d, J = 14.7 Hz, 1H), 1.94 – 1.77 (m, 2H), 1.55 (m, J = 52.3, 39.8,
11.7, 6.8 Hz, 9H), 1.22 – 1.10 (m, 1H), 1.08 (s, 3H), 1.06 – 0.97 (m, 1H), 0.93 (d, J = 6.7
Hz, 3H), 0.90 (d, J = 7.3 Hz, 4H), 0.87 – 0.82 (m, 3H).
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C NMR (126 MHz, CDCl3) δ

166.5, 155.9, 132.5, 129.8, 122.1, 120.1, 116.5, 72.8, 57.6, 51.8, 45.7, 42.2, 40.2, 33.7,
30.7, 29.9, 27.5, 24.9, 22.9, 21.5, 18.8, 18.2, 13.8. IR (film) ʋ max 3400 (br s), 3215, 2953,
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2941, 2867, 2775, 1610, 1584, 1485, 1466, 1364, 1301, 1250, 1208, 1137, 1086, 1062,
1032, 937, 917, 715. DART-HRMS: m/z calculated for C23H34O3NH4: 376.2853
[M+NH4]+. Found: 376.2868.
(1R,3aR,4S,7aR)-7a-methyl-1-((R)-nonan-2-yl)octahydro-1H-inden-4-yl 3-hydroxybenzoate (102): 1H NMR (500 MHz, CDCl3) δ 7.65 (dd, J = 7.8, 1.3 Hz, 1H), 7.59 (dd, J
= 2.6, 1.5 Hz, 1H), 7.34 (t, J = 7.9 Hz, 1H), 7.10 – 7.04 (m, 1H), 5.45 (s, 2H), 5.43 (s,
1H), 2.12 – 2.05 (m, 2H), 2.05 – 1.98 (m, 1H), 1.93 – 1.76 (m, 3H), 1.65 (s, 2H), 1.62 –
1.41 (m, 9H), 1.40 – 1.19 (m, 7H), 1.04 (d, J = 10.2 Hz, 3H), 0.99 (t, J = 6.9 Hz, 3H),
0.89 (dd, J = 6.8, 2.0 Hz, 3H).
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C NMR (126 MHz, CDCl3) δ 166.7, 156.1, 132.5, 129.8,

122.1, 120.2, 116.5, 72.9, 58.7, 51.8, 42.1, 40.0, 33.9, 30.9, 30.7, 30.3, 29.9, 29.8, 29.6,
27.5, 22.9, 22.6, 18.8, 18.2, 13.9, 13.8. IR (film) ʋ max 3456 (br s), 2992, 2950, 2926,
2907, 1712, 1699, 1485, 1466, 1364, 1346, 1250, 1208, 1137, 1086, 1062, 1032, 937,
917, 715, 656. DART-HRMS: m/z calculated for C26H40O3NH4: 418.3982 [M+NH4]+.
Found: 418.3301.
(1R,3aR,4S,7aR)-1-((R)-4,4-dimethylpentan-2-yl)-7a-methyloctahydro-1H-inden-4-yl
3-hydroxybenzoate (103): 1H NMR (500 MHz, Chloroform-d) δ 7.79 – 7.54 (m, 2H),
7.44 – 7.31 (m, 1H), 7.18 – 6.99 (m, 1H), 5.80 (d, J = 12.1 Hz, 1H), 5.42 (s, 1H), 2.17 –
2.07 (m, 1H), 2.07 – 1.98 (m, 1H), 1.97 – 1.67 (m, 3H), 1.66 – 1.43 (m, 6H), 1.37 (dd, J =
14.4, 7.0 Hz, 2H), 1.25 (d, J = 10.1 Hz, 1H), 1.20 – 1.11 (m, 1H), 1.09 (d, J = 1.7 Hz,
1H), 1.06 – 0.99 (m, 1H), 0.99 – 0.85 (m, 11H).13C NMR (126 MHz, CDCl3) δ 166.5,
155.8, 132.3, 129.7, 121.9, 120.0, 116.4, 72.8, 57.8, 51.7, 49.7, 42.0, 40.0, 32.4, 31.1,
30.5, 30.4, 30.4, 29.7, 27.7, 22.7, 22.6, 18.0, 13.4. IR (film) ʋ max 3430 (br s), 3146, 3017,
2950, 2931, 2867, 1671, 1613, 1584, 1485, 1466, 1374, 1346, 1250, 1208, 1137, 1088,
1061, 1032, 937, 917, 755, 702, 666. DART -HRMS: m/z calculated for C24H36O3NH4:
390.3008 [M+NH4]+. Found: 390.3030.
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(1R,3aR,4S,7aR)-1-((R)-4-ethylhexan-2-yl)-7a-methyloctahydro-1H-inden-4-yl 3hydroxybenzoate (104): 1H NMR (500 MHz, CDCl3) δ 7.65 (m, J = 7.7, 1.1 Hz, 1H),
7.58 (dd, J = 2.7, 1.5 Hz, 1H), 7.35 (m, J = 7.9, 2.1 Hz, 1H), 7.07 (m, J = 8.1, 2.7, 1.1 Hz,
1H), 5.42 (q, J = 2.9 Hz, 1H), 5.29 (d, J = 4.4 Hz, 1H), 2.16 – 1.98 (m, 2H), 1.98 – 1.76
(m, 2H), 1.64 – 1.29 (m, 8H), 1.28 – 1.04 (m, 8H), 1.01 – 0.79 (m, 10H).

13

C NMR (126

MHz, CDCl3) δ 166.5, 155.8, 132.6, 129.84122.2, 120.0, 116.5, 72.8, 57.8, 51.8, 42.2,
39.8, 37.4, 33.6, 30.7, 29.9, 27.6, 26.8, 24.6, 22.9, 18.9, 18.2, 13.9, 11.5, 10.2. IR (film)
ʋmax 3324 (br s), 3215, 2953, 2941, 2867, 2775, 1610, 1584, 1485, 1466, 1364, 1341,
1250, 1208, 1137, 1086, 1062, 1032, 937, 917, 715, 656. DART-HRMS: m/z calculated
for C25H38O3NH4: 404.3208 [M+NH4]+. Found: 404.3230.
(1R,3aR,4S,7aR)-1-((2R,5R)-5,6-dimethylheptan-2-yl)-7a-methyloctahydro-1Hinden-4-yl 3-hydroxybenzoate (109): 1H NMR (500 MHz, CDCl3) δ 7.62 (m, 1H), 7.58
(m, 1H), 7.32 (m, 1H), 7.05 (m, 1H), 5.58 (m, 1H), 5.39 (m, 1H), 2.05 (m, 1H), 1.98 (m,
1H), 1.81 (m, 2H), 1.65 (m, 1H), 1.53 (m, 5H), 1.40 (m, 4H), 1.29 (m, 8H), 1.02 (s, 3H),
0.93 (d, J = 6.6 Hz, 3H), 0.86 (d, J = 6.9 Hz, 3H), 0.78 (dd, J = 6.8, 3.4 Hz, 6H). 13C
NMR (126 MHz, CDCl3) δ 166.4, 155.7, 132.2, 129.6, 121.9, 119.9, 116.3, 72.6, 56.2,
51.5, 41.9, 39.8, 39.0, 35.8, 33.4, 31.4, 30.5, 30.4, 29.7, 27.0, 22.6, 20.5, 18.7, 18.0,
17.5, 15.4, 13.5. IR (film) ʋ max 3400, 2956, 2939, 2868, 2858, 1700, 1684, 1601, 1589,
1294, 1217, 1160, 1110, 946, 756, 680, 669. DART -HRMS: m/z calculated for
C26H40O3NH4: 418.3321 [M+NH4]+. Found: 418.3306.
(1R,3aR,4S,7aR)-1-((2R,5S,E)-5,6-dimethylhept-3-en-2-yl)-7a-methyloctahydro-1Hinden-4-yl 3-hydroxybenzoate (111): 1H NMR (500 MHz, CDCl3) δ 7.61 (m, 2H), 7.31
(m, 1H), 7.06 (m, 1H), 5.98 (br s, 1H), 5.39 (m, 1H), 5.18 (m, 2H), 2.01 (m, 3H), 1.81 (m,
2H), 1.68 (m, 1H), 1.49 (m, 6H), 1.24 (m, 4H), 1.15 (m, 1H), 1.04 (m, 3H), 1.02 (d, J =
6.5 Hz, 3H), 0.91 (d, J = 6.8 Hz, 3H), 0.73 (m, 6H). 13C NMR (126 MHz, CDCl3) δ 162.0,
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136.8, 127.9, 127.4, 125.1, 122.4, 120.7, 111.8, 108.2, 72.5, 69.4, 56.7, 56.5, 52.6, 51.6,
42.0, 41.8, 40.4, 39.9, 39.5, 39.4, 35.9, 35.9, 35.4, 35.2, 33.6, 30.6, 28.0, 27.1, 27.0,
23.8, 23.7, 22.8, 22.6, 22.5, 18.6, 18.5, 18.0, 17.4, 13.5, 13.4. IR (film) ʋ max 3184, 3146,
3017, 2950, 2931, 2867, 1671, 1613, 1584, 1485, 1466, 1374, 1346, 1325, 1301, 1250,
1208, 1137, 1088, 1061, 1032, 937, 917, 883, 800, 755, 702, 666. DART -HRMS: m/z
calculated for C26H38O3NH4: 416.3165 [M+NH4]+. Found: 416.3171.
(1R,3aR,4S,7aR)-1-((S)-1-hydroxypropan-2-yl)-7a-methyloctahydro-1H-inden-4-yl 3hydroxybenzoate (113): 1H NMR (500 MHz, CDCl3) δ 7.63 (d, J = 7.6 Hz, 1H), 7.56 (d,
J = 2.1 Hz, 1H), 7.34 (t, J = 7.8 Hz, 1H), 7.09 (dd, J = 8.2, 2.8 Hz, 1H), 5.66 (s, 1H), 5.39
(d, J = 3.3 Hz, 1H), 4.76 (s, 1H), 4.32 (dd, J = 10.8, 3.6 Hz, 1H), 4.12 (m, J = 17.6, 11.1,
5.6 Hz, 1H), 2.10 (m, J = 13.3, 3.4 Hz, 1H), 2.04 – 1.85 (m, 2H), 1.83 – 1.74 (m, 3H),
1.61 (m, J = 8.9, 5.0 Hz, 4H), 1.44 (m, J = 14.2, 6.1, 4.8 Hz, 2H), 1.14 (d, J = 6.6 Hz,
3H), 0.97 (d, J = 7.8 Hz, 3H).
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C NMR (126 MHz, CDCl3) δ 166.7, 156.1, 132.1, 129.8,

122.0, 120.3, 116.4, 74.768, 70.0, 53.1, 51.0, 42.2, 39.6, 35.8, 30.4, 26.2, 22.6, 17.6,
17.4, 13.0. IR (film) ʋ max 3621, 3464, 3385 (br s), 3019, 2951, 2868, 1599, 1589, 1466,
1453, 1366, 1295, 1215, 1157, 1106, 1075, 1062, 982, 946, 886, 755, 680, 668. DART HRMS: m/z calculated for C20H27O3: 315.1960 [M-OH]+, Found: 315.1983.
3. Biological evaluation
3.1 Experimental protocols
Cell line maintenance and general protocols: C3H10T1/2 cells were purchased
from American Type Culture Collection (ATCC). ASZ001 cells were a generous gift of
Dr. Ervin Epstein (Children’s Hospital of Oakland Research Institute) . Gibco by Life
Technologies culture media was purchased from ABI. C3H10T1/2 cells were cultured in
BME (Gibco) supplemented with 10% FBS (Atlanta Biologicals, Premium Select), 1% L glutamine (Cellgro; 200 nM solution), and 0.5% penicillin/streptomycin (Ce llgro; 10,000
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I.U./mL penicillin, 10,000 μg/mL). ASZ001 cells were cultured in 154CF media,
supplemented with 2% FBS (chelexed, heat-inactivated), 1.0% penicillin/streptomycin,
and a final concentration of 0.05mM CaCl 2. Cells were maintained using the media
described above (denoted “growth media”). Media denoted as “low FBS” contained 0.5%
FBS and the same percentage of other supplements as specified for growth media (“low
FBS” media with this percentage FBS was used for C3H10T1/2 cell assays). Following
plating and 24 hr growth period, no FBS supplemented media was used for ASZ001 cell
assays. All cells were grown in Corning Cell Culture, canted neck T75 or T150 flasks
(Fisher Scientific) in an Autoflow IR water-jacketed CO2 incubator (37°C, 5% CO 2).
Experiments with C3H10T1/2 cells were performed in BD Falcon sterile 60 mm dishes.
500,000 cells at ~80% confluence were plated in 5 mL media. Experiments with ASZ001
cells were performed in BD Falcon 35 mm dishes or in 6-well, 35mm plates. For the
ASZ001 line, 300,000 cells at ~80% confluence were plated in 2 mL media. DMSO was
used as solvent to prepare all drug solutions and the final DMSO concentration did not
exceed 0.3%. 20α-hydroxycholesterol, 22(S)-hydroxycholesterol (Oxysterol/Oxy) and
VD3, for biological studies, were purchased from Sigma-Aldrich.
Analysis of Hh and VDR target gene expression in C3H10T1/2 cells: Cells were
plated in growth media at ~80% confluence. Once cells reached confluence
(approximately 24 hr), growth media was removed and replace d with low FBS media (5
mL). This was followed by addition of Oxy, Oxy and analogue, or DMSO (vehicle
control). Cells were incubated (37°C, 5% CO 2) for 24 hr period and RNA was isolated
and evaluated by qRT-PCR analysis as described previously in Chapter 2. Data was
analyzed using GraphPad Prism 5 and IC 50 values computed as mean ± SEM from at
least three separate experiments performed in triplicate.
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Analysis of Hh and VDR target gene expression in murine-derived BCC
(ASZ001) cells: Cells were plated in growth media at ~80% confluence. After 24 hr,
growth media was removed and replaced with no FBS media (2 mL). Cells were then
incubated for an additional 24 hrs. After this time, addition of DMSO (vehicle control) or
analogues was performed. Cells were incubated (37°C, 5% CO2) for 48 hr and RNA was
isolated and evaluated by qRT-PCR analysis as described previously. Data was
analyzed using GraphPad Prism 5 and IC 50 values computed as mean ± SEM from at
least three separate experiments performed in triplicate.
3.2 Results & discussion

Figure 4. VD3 based hybrid side chain analogues.
This series of hybrid side chain analogues prepared for evaluation can be
broadly categorized into two groups, i.e. hydrocarbon containing and non -hydrocarbon
containing side chain analogues (Figure 4). Further, the first group has representatives
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for linear alkyl side arms (93, 94, 98, 99, 100 and 102), branched alkyl chains (95, 101,
103, 104, 109) branched alkenyl side chains (111) as well as an aromatic side chain
derivative (96). On the other hand, analogue (113) is the only non-hydrocarbon
containing side chain analogue.
The initial evaluation of all hybrid VD3 side chain analogues as Hh pathway
inhibitors was performed at a single dose (5 μM) by monitoring endogenous Gli1 mRNA
levels in C3H10T1/2 cells following standard assay protocols

108,

111

. At this

concentration, excluding 99, 101, 102, and 103, other derivatives maintained similar
potency (0.5-10% Gli1 mRNA expression). Moreover, inhibitory activities of the latter
were comparable to the previously identified VD3-based lead scaffold 87 and improved
compared to that of VD3 (Table 1). Thereafter, relative mRNA expression levels of Gli1
were examined after treatment of C3H10T1/2 cells with a lower concentration (2.5 μM)
(Table 1). At this dose, differences between assay readouts from treatments with
different analogues were more pronounced and thus it was possible to identify
analogues that maintained potent anti-Hh activity even at a lower concentration. Based
on the data from treatments at two different doses, the optimum length of linear side
chain proved to be critical in maintaining potent Gli1 inhibitory activity. Derivatives with
shorter 93, 94, 98 and 99 or longer 102 chain lengths than the naturally occurring sixcarbon side arm present in VD3 suffered losses in potency. In agreement with this
general trend, 100 retained Hh antagonistic activity similar to the lead structure 87 in this
cellular model. Several interesting effects on the inhibitory activity profile were observed
on introduction of branched side chains. Analogues with very short branched chains 101
and 103 were less active than the parent scaffold. However, iso and ante-iso branching
incorporated into five-carbon long side chain (95 and 104 respectively) salvaged the loss
in potency seen in the unbranched derivative with a comparable length side arm ( 99). In
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terms of favorable features unraveled so far, 109 had a combination of extended sixcarbon link primary chain along with terminal and non-terminal branching in the same
molecule. Nonetheless, instead of the expected synergistic outcome of all these features
incorporated in one derivative, deleterious effects on the level of Gli1 inhibition were
observed. Interestingly, an additional unsaturation present in the side chain of this
molecule helped to restore the diminished activity. Consequently, analogue 111 with
comparatively rigid side arm exhibited slightly greater than two-fold improvement in
activity as compared to relatively flexible analogue 109. Finally, no improvement in
activity was evident for the aromatic side chain containing derivative 96 or hydroxyl side
chain analogue 113. It is unclear whether the loss of activity in these cases can be
attributed singularly to the planar/polar nature of these substituents respectively.
Analysis of specific contributions of the length of the connecting carbon chains extending
these functionalities spatially remains the subject of further investigation.
Table 2. Gli1 inhibitory activity in C3H10T1/2 cells.
Analogue

a

Relative Gli1 mRNA (%)
5 µM treatment
2.5 µM treatment

VD3

31.7 ± 0.7

71.4 ± 2.1

87
93

1.9 ± 0.5
1.31 ± 0.1

15 ± 2.0
49.8 ± 1.8

94

7.7 ± 5.5

69.8 ± 27.2

95

2.9 ± 0.3

23.0 ± 4.3

96

7.2 ± 1.8

88.4 ± 55.4

98
99

0.7 ± 0.3
38.4 ±4.15

33.9 ± 13.1
52.3 ± 13.2

100

1.1 ± 0.3

17.3 ± 3.6

101

74.4 ± 0.7

90.1 ± 12.5

102

29.9 ± 16.1

54.4 ± 9.7

103

32.4 ± 28.93

49.1 ± 19.6

104
109

0.49 ± 0.2
9.2 ± 6.1

17.4 ± 4.5
40.4 ± 9.5

111

2.2 ± 0.5

15.6 ± 0.9

113

10.2 ± 6.1

56.9 ± 10.2

a

Relative Gli1 mRNA levels w hen oxysterol treatment is equivalent to 100%.
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After establishing the effects on Hh inhibitory activity by varying the nature of CDring appendages and thereby identifying favorable modifications, we directed our efforts
towards assessing their effects on the selectivity profile of representative analo gues.
Previously, VD3 was shown to be a non-selective inhibitor of the Hh pathway,
presumably due to its propensity to undergo metabolic transformation to form calcitriol
and activate canonical VDR signaling 108. It is noteworthy that as per the known route to
such biotransformations, hydroxylations of the A-ring and the CD-ring side chain are
required to yield ligands for VDR activation (Chapter 2, Figure 3). Since the
modifications of A-ring led to improved selectivity for potent analogue 87, we were
interested in studying the repercussions of further altering the side chain region of this
lead compound.
Table 3. VDR related activity mediated by hybrid side chain analogues.
b

Analogue

Relative Cyp24A1 mRNA

VDR Binding Conc.

VD3

4004 ± 56

>100 µM

87
93

10.5 ± 2.1
0.7 ± 0.2

>100 µM
>100 µM

94

4.8 ± 0.9

>100 µM

95

2.8 ± 0.03

>100 µM

96

3.8 ± 0.1

>100 µM

98
99

1.1 ± 0.3
4.9 ± 0.5

>100 µM
>100 µM

100

4.4 ± 0.03

>100 µM

101

2.5 ± 1.0

>100 µM

102

3.8 ± 0.7

>100 µM

103
104

7.9 ± 1.4
0.6 ± 0.02

>100 µM
>100 µM

109

1.1 ± 0.02

>100 µM

111

6.8 ± 0.02

>100 µM

113

>100 µM
0.4 ± 0.1
Values represent Cyp24A1 mRNA expression level in cultured cells w hen DMSO set as 1.0.

b

None of these derivatives directly bind to VDR as measured in the previously
described in vitro VDR binding assay even at a high concentration of 100 µM (Table 3).
Since C3H10T1/2 cells respond to VDR activation with robust up-regulation of Cyp24A1,
a well-characterized target gene of canonical vitamin D signaling; we then studied off 76

target effects mediated due to potential metabolism of VD3 analogues in this system
(Table 3). Overall, every hybrid side chain analogue maintained the selectivity for Hh
inhibition without concomitant activation of VDR signaling. Moreover, analogues such as
95, 100, 104 and 111 afforded slightly improved selectivity over 87 while maintaining
better potency for Hh inhibition. Based on the fact that changing the side chain regio n
didn’t have drastic consequences on the selectivity profile, it can be hypothesized that
optimum changes to the A-ring region can suffice to mitigate side effects of the original
VD3 scaffold. However, additional fine tuning of selectivity can be achieve d by above
noted alterations to the side chain region.
Previous studies evaluating Hh pathway inhibition in cultured cancer cells have
suggested that the majority of in vitro cancer cell lines do not appropriately model in vivo
Hh signaling. With this in mind, we sought to characterize VD3 and related analogues in
a cell line, ASZ001, which has shown initial promise as in vitro model of oncogenic Hh
signaling. The ASZ001 cell line was developed from a visible BCC tumor isolated from a
Ptch1+/- mouse

163

. These cells demonstrate loss of the wildtype Ptch1 allele, high

baseline expression of Gli1, and cellular morphology similar to Hh -dependent BCC
tumors. In addition, treatment of these cells with either Cyc or VD3 resulting in Gli1
down-regulation has been previously reported 110, 163. Previous studies performed in this
cell line demonstrated that Gli1 down-regulation by VD3 in ASZ001 was more robust and
reproducible following a 48 h compound incubation

110

. Preliminary evaluation in our lab

was consistent with a 48 h incubation period resulting in reproducible Gli1 down regulation induced by GDC-0449 or Cyc. For this reason, all data presented from this
cell line were obtained at this time point.
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Figure 5. Hh specific activity of hybrid side chain analogues in ASZ001 cells.
Initially, we evaluated the Hh specific activity of the hybrid side chain analogues
in the ASZ001 cells at a single dose of 2.5 μM by quantifying relative mRNA expression
levels of Hh responsive gene, Gli1, and VDR dependent gene, Cyp24A1, simultaneously
(Figure 5). It had been previously established in our lab that the IC 50 for VD3 downregulation of Gli1 in ASZ001 cells correlated well with that obtained in the C3H10T1/2
fibroblasts, however; analogue 87 proves to be less effective in this model
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113, 114

.

Consistent with that observation, the extent of Gli1 downregulation in this cellular system
by hybrid side chain derivatives was less than the levels observed in its MEF
(C3H10T1/2) counterpart. The analogues demonstrating most prominent Hh inhibitory
activity included 94, 95, 96, 99, 102 and 113. While the selective and potent Hh
antagonistic activity of 95 was consistent with its activity profile previously identified in
C3H10T1/2 cells. It was intriguing to note that several of the more active analogues in
ASZ001 cells such as linear side arm-containing analogues (94, 99 and 102),
hydroxylated side arm-containing analogue (113) and aromatic functional group
containing (96) had demonstrated modest Hh inhibitory activities in C3H10T1/2 cells.
Taking into account the comparatively higher Cyp24A1 expression mediated by 99 and
102, the improved Hh inhibiton as a result of crosstalk between signaling cascades can
be speculated. Next, although 96 and 113 did not demonstrate increased levels of
Cyp24A1, these analogues caused excessive cell death at higher doses (5 μM and
above) suggestive of additional non-specific mechanisms of toxicity. Nonetheless, the
plausible reason for improved anti-Hh activity of 94 is unclear. Next, derivatives that
maintained slightly less Gli1 inhibition than the above discussed analogues included 93,
100, 103 and 104. While their Hh inhibitory activities were comparable to that of VD3,
off-target effects via VDR signaling were minimal as depicted by low Cyp24A1
expression. Finally, analogues that failed to reduce Gli1 expression in ASZ001 included
98, 101, 109 and 111. Once again, the drastic loss in activity of 111 in ASZ001 cells is in
total contrast with its excellent potency observed in C3H10T1/2 cells. Taken together,
there was a lack of definitive SAR trend in this cell based assay and further studies are
required to corroborate the theories proposed to explain the discrepancies.
Based on the preliminary screening of active and specific Hh inhibitors, we
decided to conduct further studies on analogues that exhibited an optimum
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activity/selectivity ratio across both cellular systems. Therefore, we conducted
concentration dependent analysis of Gli1 inhibitory potential of analo gues 95, 100 and
104 in both Hh signaling inducible MEF cells (C3H10T1/2) and murine BCC cells
(ASZ001) (Figure 12). When tested in C3H10T1/2 cells, all three derivatives
demonstrated low micromolar IC 50 values for Gli1 downregulation. In ASZ001 cells, 95
maintained comparable low micromolar potency. Although, 100 and 104 retain Hh
inhibitory activity, slightly higher IC 50 values were recorded.
Table 4. Determination of IC50 values in C3H101/2 cells and ASZ001 cells.
Analogue

Structure

IC50 (μM)
C3H10T1/2

ASZ001

95

1.13 ± 0.56

1.61 ± 0.15

100

1.10 ± 0.37

6.57 ± 2.78

104

1.14 ± 0.45

4.98 ± 2.87

4. Conclusion
With the goal of identifying improved Hh antagonists, we studied the effects of
modifying the side chain region of VD3. During the initial phase of this study, a VD3
based Hh selective lead compound (87, IC50 = 0.74 ± 0.1 μM) was identified in a parallel
project. Subsequently, our investigation on side chain analogues of VD3 proceeded with
altered CD-ring appendages installed on the novel VD3 based lead compound. A series
of fourteen diverse side chain derivatives were prepared and evaluated in two different
cellular models of Hh inhibition. Overall, linear or moderately branched hydrocarbon
chains of five/six carbon links proved to be optimum for potent and selective anti -Hh
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activity. Analogue 95 showed consistent improved performance in various cellular and
other in vitro assays designed to determine Hh inhibition and VDR activation.
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CHAPTER IV: Design, Synthesis and Evaluation of Itraconazole Analogues
Incorporating Modified Side Chains as Hedgehog Pathway Inhibitors

82

1. Introduction
One of the latest challenges to emerge in the discovery and development of safe and
efficacious Hh inhibitors as anti-cancer agents is the retention of comparable activity
against the drug-resistant forms of the hyperactive signaling cascade

89

. Recently

identified as a potent inhibitor of the Hh pathway (IC50 approximately 800 nM)

116

,

itraconazole (ITZ) represents an extremely promising scaffold for the development of an
improved class of Hh inhibitors for two important reasons. First, being a well-studied and
widely used FDA approved antimycotic drug, the PK properties and safety profile of ITZ
is very well documented 164. Thus, the strategy of repurposing this previously approved
drug will simplify and expedite the otherwise long-drawn process of drug discovery and
clinical approval. Second, a recent study detailing the ability of ITZ to maintain potent
inhibition of Hh signaling even in the presence of multiple mutant forms of Smo that
confer resistance to either GDC-0449 or NVP-LDE225 was reported

101

. This finding is

especially significant in the context of developing anti-Hh agents active against drug
resistant cases of BCC and MB.
ITZ is a member of the triazole class of antifungal agents that exerts its
antimycotic effects through potent inhibition of lanosterol 14α-demethylase (14LDM/
CYP51), a cytochrome P450 enzyme that catalyzes the oxidative conversion of
lanosterol to ergosterol, a major component of fungal cell membranes

165

. The main

structural regions of ITZ are a triazole-dioxolane portion, a central phenyl-piperizinephenyl linker region and a side chain appended triazolone region (Figure 1). Further, the
molecule possesses three chiral centers, two of which are on the dioxolane ring (2 and
4) while the third exists on the sec-butyl side chain (2’). Out of the eight possible
stereoisomers, a mixture of four cis-isomers (1:1:1:1) is marketed as the antifungal drug.
Previous investigations have confirmed that ITZ mediated Hh inhibition is unrelated to
the 14-α-lanosterol demethylase inhibition accountable for its anti-fungal activity
83

116

.

Following the identification of ITZ as Hh inhibitor, only a single report detailing SAR for
ITZ inhibition of Hh signaling has been reported to date. These studies focused solely on
incorporating modified alkyl substituents into the ITZ side chain

120

.

Figure 1. Structure , stereo-centers and regions of ITZ.
Despite the expected favorable outcomes of exploring the ITZ molecule for
developing novel Hh inhbitors, several key tasks remain. Identifying the Hh inhibitory
pharmacophore of ITZ is critical for guiding further modifications to suit the current
purpose and enhance the potency and efficacy of the parent moiety by suitable
modifications of the active core. Moreover, this knowledge will allow us to further
improve the physicochemical features and bioavailability of second generation ITZ
analogues which can be critical especially for clinical use in MB patients where blood brain-barrier (BBB) penetration and accumulation is of utmost significance. Previous
studies undertaken in Shh-Light II cells have indicated that other azole drugs
(Ketoconazole, Fluconazole, Miconazole and Clotrimazole) that share structural features
with ITZ and have comparable or better anti-fungal activities, exhibit decreased
potencies as inhibitors of Smo

116

. To corroborate these findings, we evaluated several

commercially available, structurally related triazole and imidazole anti-fungals for their
ability to inhibit Hh signaling at 1 μM in the C3H10T1/2 murine fibroblast cell line when
recombinant Sonic Hh protein was used to up-regulate Hh signaling (Figure 2, Table 1).
We discovered that only Posaconazole (PSZ) maintained Hh inhibition comparable to
ITZ in this assay. Interestingly, ITZ and PSZ share considerable structural and spatial
similarity with certain differences in the triazole-dioxolane and triazolone side chain
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regions of the molecules. Therefore, we were interested in studying the effects of
integrating the structural features of PSZ with ITZ as hybrid second generation
analogues. Keeping in mind the issues of poor water solubility and low bioavailability of
ITZ

166

, initial efforts were directed towards the generation of hydroxylated side chain

containing ITZ derivatives to simultaneously achieve the goals of improving potency as
well as physicochemical and pharmacokinetic attributes. A report of our current progress
in identifying a suitable synthetic route to prepare ITZ derivatives with stereochemically
defined hydroxylated side chains as mimics of the PSZ side arm and a brief description
of preliminary biological evaluation is presented in this chapter.

Figure 2. Structure of commercial azole antifungal drugs tested for Hh inhibition .
Table 1. Hh Inhibition for Commercially Available Azole Antifungals.
Compound

Relative Gli1 mRNA (%)

Compound

Relative Gli1 Mrna (%)

Recombinant SHh

100

Voriconazole

48.4 ± 7.4

ITZ

4.8 ± 2.1

Ravuconazole

35.2 ± 1.4

PSZ

5.1 ± 3.6

Albaconazole

44.5 ± 6.2

Fluconazole

75.3 ± 1.6

Terconazole

59.0 ± 10.6

Miconazole

63.2 ± 8.1

Ketoconazole

43.9 ± 0.3

a

Relative Gli1 mRNA levels w hen SHh treatment is equivalent to 100%.
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2. Synthesis of ITZ-PSZ hybrid analogues
2.1 Overview
Preparation of ITZ-PSZ hybrid analogues was accomplished through an optimized
multistep route specifically planned for facile medicinal chemistry purposes of accessing
stereochemically defined hydroxylated side chain derivatives of ITZ. The essential
synthetic transformations can be classified as follows: (a) synthesis of hydroxylated side
chain precursors (A), (b) synthesis of MOM-ITZ triazolone linker region intermediate (B),
(c) alkylation of MOM-ITZ triazolone linker region intermediate (C) followed by
deprotection to generate necessary phenolic intermediates (D), (d) synthesis of tosylated
dioxolane intermediate (E) and (e) nucleophilic displacement of the tosyl moiety by
phenolic precursors to generate final analogues (Scheme 1).

Scheme 1. Retrosynthesis of ITZ-PSZ hybrid analogues
Preparation of hydroxylated side chain precursors (A) was carried out using
stereochemically defined starting materials methyl (R)-2-hydroxylpropanoate (122) or
methyl (S)-2-hydroxylpropanoate (123). Masking the free hydroxyl groups as silyl ethers,
86

the resulting intermediates (124) and (125) were subjected to reduction by DIBAL-H to
yield the corresponding aldehyde derivatives (126) and (127). Even with strictly
controlled temperature of -78 ºC, some of the starting esters underwent complete
reduction to form the corresponding alcohol derivatives ( 128 and 129) and selective
generation of required aldehyde precursors proceeded with modest yields. Hence,
attempts to reoxidize the hydroxylated derivative back to the aldehyde stage were made
by utilizing PDC and Dess Martin Periodinane reagents respectively. While reaction with
PDC led to the generation of partial oxidation product i.e. necessary aldehyde along with
unwanted complete oxidation product (corresponding carboxylic acid), the reaction
proceeded more successfully with the Dess Martin Periodinane conditions. Despite the
success, these routes of recycling the alcohol derivatives back to the aldehyde
precursors proved less favorable as there was unnecessarily addition to the overall
steps required to generate final compounds. Therefore, we employed the previous
strategy of ‘selective’ reduction with DIBAL-H on a larger scale reaction to prepare
necessary amounts of intermediates (126 and 127) taking into consideration the
expected reaction yields. These intermediates were then subjected to nucleophilic
addition by ethylmagnesium bromide to prepare and isolate precursors ( 130-133). As
expected, the presence of bulky silyl ether protecting group on th e adjacent hydroxyl
directed the addition following the Felkin Ahn model, generating the predominantly ‘anti’
derivatives with an overall yield of 60-72% in a 3:1 (anti:syn) ratio. Finally, the free
hydroxyl moieties were converted to corresponding brosyl functionalities to yield
intermediates (A: 134-139) (Scheme 2).

87

Scheme 2. Synthesis of hydroxylated side chain precursors (A).
A previously reported literature protocol was followed for the synthesis of MOMITZ triazolone linker region (B: 144)

120

. We proceeded by coupling commercially

available N-(4-hydroxylphenyl)-piperazine (140) and 1-chloro-4-nitrobenzene (141) to
yield N-(4-hydroxyphenyl)-N′-(4-nitrophenyl)-piperazine derivative. This crude product
was directly used to react with methoxymethyl chloride to afford the MOM-protected
intermediate (142). Subsequent reduction of the nitro group of (142) afforded the
corresponding

amine

derivative

precursor

necessary

for

the

synthesis

of

phenylcarbamate derivative (143). Ultimately, synthesis of the triazolone heterocycle
was accomplished via formation of the semicarbazide intermediate from precursor ( 143)
(Scheme 3).

Scheme 3. Synthesis of MOM-ITZ triazolone linker region intermediate (B).
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Next, alkylation of triazolone intermediate (B) was attempted by using Cs 2CO3 in
the presence of 18-crown-6 at room temperature to generate the anion of (B) to facilitate
SN2 displacement of the brosylate intermediates (A)

120

. However, with secondary

brosylates such as (135), the reaction failed to proceed under these conditions in either
DMF or DMSO (Table 2). Thereafter, the reaction was subjected to an elevated
temperature of 80 ºC affording better results

167

. Under these revised conditions, the

reactions proceeded to completion to form intermediates ( 145) and (146), however;
unreacted starting materials were recovered when using the sterically hindered
brosylates (134-137). Subsequently, the reaction mix was heated at 50 ºC with the base
(Cs2CO3) and the chelator (18-crown-6) to enhance the nucleophile formation before
addition of sterically crowded brosylate intermediates. Further, the reaction was heated
overnight at 80 ºC to facilitate the complete consumption of starting materials leading to
improved yields of (C: 147-150). The final step to generate phenolic precursors (D: 151156) was accomplished by global deprotection of methoxymethyl and silyl ether groups
using trifluoroacetic acid (Scheme 4).

Scheme 4. Synthesis of phenolic precursors (D).
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Table 2. Optimization of reaction conditions for alkylatio n of (B).
Reaction
Reaction conditions

Observations
yields

CsCO3, 18-crow n-6, DMSO, rt, 1h; (135), rt 12h

No reaction

-

CsCO3, 18-crow n-6, DMF, rt, 1h; (135), rt 12h

No reaction

-

CsCO3, 18-crow n-6, DMF, rt, 1h; (135), 80ºC, 12h

Some unreacted starting material

30%

CsCO3, 18-crow n-6, DMF, 50 ºC , 1h; (135), 80ºC, 12h

Reaction complete

57%

CsCO3, 18-crow n-6, DMF, rt, 1h; (138 /139), 80ºC, 12h

Reaction complete

62%

Formerly reported literature methods for preparing the tosylated -dioxolane
intermediate (E) were adopted with slight modifications to generate the intermediate as a
mixture of both cis and trans isomers

168, 169

. Beginning with a protected glycerol

intermediate (157), the free primary hydroxyl group was first transformed to the
corresponding tosylate (158), followed by a deprotection step to yield mono-tosylated
glycerol (159). In parallel, trichloroacetophenone (160) was utilized to facilitate
substitution of chloro group with triazole functionality leading to precursor (161).
Ultimately, triflic acid mediated ketalization using (159) proceeded to generate
intermediate (E: 162) as a mixture of cis (major product) and trans (minor product)
isomers (Scheme 5).

Scheme 5. Synthesis of tosylated dioxolane intermediate (E).
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The final step consisted of coupling the tosyl-dioxolane intermediate (E) with
each of the phenolic precursors (D). Initial attempts of base assisted generation of the
phenoxy nucleophile were performed using NaH in DMSO at elevated temperatures (50 90 ºC) 120, 170. Adopting this protocol, final analogues (163 and 164) were synthesized in
modest yields (Scheme 6). However, the purification steps of these analogues proved
extremely challenging owing to the difficulties of removal of DMSO and several side
products possibly formed due to the action of NaH in DMSO in the presence of free
hydroxyl groups at elevated temperatures. Consequently, these analogues were isolated
at 80-85% purity levels as determined by NMR spectral data. Thereafter, multiple efforts
to couple tosyl-dioxolane intermediate (E) with phenolic precursors containing bulkier
hydroxylated side appendages (153-156) failed. While, desired analogues were not
detected in these reaction mixtures, the starting precursors had been consumed to form
complex compounds of unknown structures. Based on the observations of typical color
changes associated with ylide formation, it was hypothesized that under the
aforementioned conditions, DMSO was participating in the reaction possibly through its
activation to form sulfur ylides. As an alternate, DMF was employed as a solvent to
successfully synthesize 165 with 20% yields (Scheme 6). This final coupling step is
currently underway for other phenolic precursors.

Scheme 6. Synthesis of ITZ-PSZ hybrid analogues.
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2.2 Experimental protocols
General procedure for TBS protection: To a solution of methyl (R)-2hydroxylpropanoate or methyl (S)-2-hydroxylpropanoate (5 g, 1 eq.) in anhydrous DCM
(60 mL) was added imidazole (4.25 g, 1.3 eq.), and the mixture was stirred for 10 min at
0 °C. To this solution tert-butyldimethylsilyl chloride (8.68 g, 1.2 eq.) was added at 0 °C
and the mixture was allowed to warm to RT and stirred overnight. After completion of the
reaction, the mixture was diluted with water and extracted into DCM. The combined
extract was washed with brine, dried over anhydrous Na 2SO4 and concentrated under
reduced pressure. The crude residue was purified by column chromatography (SiO2, 05% EtOAc in hexanes) to give pure compounds (124) and (125) as colorless oils in 95 %
yields.
General procedure for reduction to aldehyde: To a cooled (-78 °C), stirred
solution of ester compounds (124) or (125) (5 g, 1 eq.) in anhydrous DCM (50 mL) was
slowly added DIBAL-H (1.0 M, 2 eq.) and stirred for 2 h. The reaction was quenched with
saturated sodium potassium tartarate (50 mL), stirred for 0.5 h and then filtered using
excess DCM. The combined organic phases were separated, washed with brine, dried
over anhydrous Na 2SO4, and concentrated under reduced pressure. The crude product
was purified by column chromatography (SiO2, 0-5% EtOAc in hexanes) to give
aldehydes (126) and (127) as a colorless liquids in 30-40 % yields.
General procedure for nucleophilic addition of Grignard reagents: Aldehyde
(126) or (127) (1 g, 1 eq.) in anhydrous THF (20 mL) was added dropwise to
ethylmagnesium bromide (3.0 M in anhydrous THF, 5 eq.) at -78 °C and the reaction
mixture was stirred for 2 h. After completion, the reaction mixture was quenched with
water and extracted into EtOAc. The combined organic layer was washed with 0.1N HCl,
brine, dried over Na 2SO4, and concentrated. The crude residue was purified by column
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chromatography (SiO2, 0-15% EtOAc in hexanes) to carefully separate the resulting
isomers (130-133) as a colorless oils in good yields [130 & 131: 72% (1:3); 132 & 133:
60% (3:1)].
General procedure for brosylation: To a solution of hydroxyl intermediate
128/129/130/131/132/133 (0.1- 0.12 g, 1 eq.) in anhydrous DCM (3-5 ml), triethylamine
(2 eq.), dimethylaminopyridine (1 eq.) and 4-bromobenzene-1-sulfonyl chloride i.e. BsCl
(1.3 eq.) were added at 0 °C. The reaction mixture was allowed to warm to RT while
stirring overnight. On completion, the mixture was diluted with DCM, washed with water,
dried over Na 2SO4 and concentrated under reduced pressure. Purification using column
chromatography (SiO2, 0-10% EtOAc in hexanes) yielded intermediates (A: 134-139) as
clear oils in 65-80% yields.
General procedure for alkylation of linker region: To a solution of the linker
region triazolone intermediate, (C), (1 eq.) in DMF was added Cs2CO3 (2 eq.) and 18crown-6 (1 eq.). The resulting mixture was stirred at 50 ºC for 1 h followed by the
addition of corresponding alkyl brosylates A: 134-139 (1.5 eq.). The reaction mixture
was stirred overnight at 80 ºC. After cooling to room temperature, the reaction mixture
was diluted with water and extracted with EtOAc. The combined organic layer was dried
over Na2SO4, filtered, and concentrated to yield the crude product. Purification by
column chromatography (SiO2, 0-3% MeOH in DCM) afforded pure products (C: 145150) as a brown solid in 30-62% yields.
General procedure for coupling phenol intermediates (D) and tosylated
dioxolane intermediate (E): To a solution of the phenol D (1 eq.) in DMF was added
NaH (a 60% dispersion in mineral oil, 5 eq.). After the mixture was stirred at 50 °C under
argon for 1 h, a solution of E (1.1 eq.) in DMF was added dropwise. After the addition,

93

the temperature was increased to 90 °C and the solution was stirred under argon
overnight. The reaction was then quenched by the addition of a 50% aqueous NaCl
solution, and the resulting mixture was extracted with CH2Cl2. The organic fractions were
dried (Na2SO4), filtered, and concentrated under vacuum to yield the crude product,
which was purified by column chromatography (SiO2, 0-5% MeOH in DCM) to afford the
desired products as white solids in 20% yields.
4-(4-(4-(4-((2-((1H-1,2,4-triazol-1-yl)methyl)-2-(3,5-dichlorophenyl)-1,3-dioxolan-4yl)methoxy)phenyl)piperazin-1-yl)phenyl)-1-((R)-2-hydroxypropyl)-1H-1,2,4-triazol5(4H)-one (163)
H NMR (500 MHz, CDCl3) δ 8.31 – 8.15 (m, 1H), 8.01 – 7.85 (m, 1H), 7.66 – 7.54 (m,

1

1H), 7.54 – 7.38 (m, 1H), 7.25 – 7.02 (m, 1H), 6.97 (s, 5H), 6.95 – 6.78 (m, 3H), 4.81 (m,
J = 25.3, 18.0, 9.1 Hz, 2H), 4.38 (m, J = 5.9 Hz, 1H), 4.26 – 3.97 (m, 1H), 3.93 (q, J =
7.6 Hz, 1H), 3.82 (m, J = 14.6, 6.7, 3.8 Hz, 2H), 3.53 (m, J = 9.6, 4.7 Hz, 1H), 3.33 –
3.16 (m, 8H), 1.64 (s, 1H), 1.27 (s, 1H).
4-(4-(4-(4-((2-((1H-1,2,4-triazol-1-yl)methyl)-2-(3,5-dichlorophenyl)-1,3-dioxolan-4yl)methoxy)phenyl)piperazin-1-yl)phenyl)-1-((S)-2-hydroxypropyl)-1H-1,2,4-triazol5(4H)-one (164)
H NMR (500 MHz, CDCl3) δ 8.29 – 8.19 (m, 1H), 7.97 – 7.85 (m, 1H), 7.64 – 7.55 (m,

1

1H), 7.49 (d, J = 2.0 Hz, 1H), 7.14 (d, J = 8.2 Hz, 1H), 6.97 (s, 4H), 6.90 – 6.74 (m, 5H),
4.81 (m, J = 25.3, 18.0, 9.1 Hz, 2H), 4.38 (p, J = 5.9 Hz, 1H), 4.25 – 3.99 (m, 1H), 3.93
(q, J = 7.6 Hz, 1H), 3.82 (m, J = 14.8, 6.6, 3.7 Hz, 2H), 3.53 (m, J = 9.6, 4.7 Hz, 1H),
3.34 – 3.16 (m, 8H), 1.64 (s, 1H), 1.27 (s, 1H).

94

4-(4-(4-(4-((2-((1H-1,2,4-triazol-1-yl)methyl)-2-(3,5-dichlorophenyl)-1,3-dioxolan-4yl)methoxy)phenyl)piperazin-1-yl)phenyl)-1-((2S,3R)-2-hydroxypentan-3-yl)-1H1,2,4-triazol-5(4H)-one (165)
H NMR (500 MHz, CDCl3) δ 8.23 (s, 1H), 8.15 (s, 1H), 7.98 (s, 1H), 7.92 (s, 1H), 7.67

1

(s, 1H), 7.60 (dd, J = 8.4, 2.5 Hz, 2H), 7.50 (t, J = 1.9 Hz, 1H), 7.48 – 7.42 (m, 2H), 7.28
– 7.25 (m, 1H), 7.15 (d, J = 8.2 Hz, 1H), 7.09 – 7.02 (m, 2H), 7.00 – 6.93 (m, 2H), 6.86 –
6.79 (m, 3H), 4.87 (d, J = 14.7 Hz, 1H), 4.81 – 4.74 (m, 2H), 4.39 (tt, J = 6.5, 4.9 Hz,
1H), 4.26 – 4.14 (m, 2H), 4.09 (m, J = 11.0, 3.5 Hz, 2H), 4.02 – 3.79 (m, 4H), 3.76 – 3.67
(m, 1H), 3.52 (dd, J = 9.7, 6.3 Hz, 1H), 3.44 – 3.35 (m, 5H), 3.30 – 3.23 (m, 5H), 2.05
(m, J = 14.6, 11.0, 7.3 Hz, 1H), 1.90 (m, J = 14.7, 7.4, 3.6 Hz, 1H), 1.64 (d, J = 8.3 Hz,
6H), 1.28 (d, J = 6.5 Hz, 5H), 0.94 (t, J = 7.4 Hz, 3H). 13C NMR (126 MHz, CDCl3) δ
153.0, 152.7, 151.4, 150.8, 146.0, 136.1, 134.3, 134.3, 133.0, 131.4, 129.6, 127.3,
127.3, 123.7 (2C), 118.5 (2C), 116.6 (2C), 115.3 (2C), 107.6, 107.2, 74.7, 70.3, 67.5,
66.2, 61.6, 53.5, 50.6 (2C), 49.2 (2C), 31.6, 22.7, 19.5, 14.1, 10.8 . IR (film) ʋmax 3436,
3181, 2933, 1646, 1511, 1456, 1385, 1348, 1277. DART-HRMS: m/z calculated for
C38H43Cl2N6O5: 735.2577 [M+H]+, Found: 735.2548.
3. Biological evaluation
3.1 Experimental protocols
Analysis of Hh target gene expression: Cells were plated and grown according to
cell line specific protocols described in Chapter 3. Recombinant SHh protein (200 ng/ ml)
was used to activate Hh signaling in C3H10T1/2 cells. RNA isolation and evaluation by
qRT-PCR analysis was performed as described in previous chapters. Data was
analyzed using GraphPad Prism 5 and IC 50 values computed as mean ± SEM from at
least three separate experiments performed in triplicate.
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3.2 Results
Table 3. Preliminary evaluation of hybrid ITZ analogues.

Gli1 mRNA IC50 Values (µM)
Analogue
C3H10T1/2 cells

ASZ cells

ITZ

0.074 ± 0.02

0.14 ± 0.02

PSZ

0.01 ± 0.005

0.54 ± 0.05

163

0.45 ± 0.09

0.15 ± 0.01

164

0.18 ± 0.02

0.10 ± 0.01

Preliminary evaluation conducted in C3H10T/12 cells revealed that both ITZ
hybrid analogues maintain potent inhibition of Gli1 mRNA expression (180 -450 nM).
Overall, the (R) hydroxyl containing analogue i.e. 163 showed two-fold loss of activity as
compared to the (S) hydroxyl derivative 164 in this cellular assay. The biological activity
profile of these analogues showed similar trends when studied in the ASZ cells. Both
derivatives strongly inhibited Gli1 mRNA expression in these cells as well (Table 3).
4. Conclusion
Discovery of potent Hh inhibitory activity mediated by ITZ opened new avenues for
drug discovery explorations based on this scaffold. A comparative analysis of Hh
inhibitory activities of various members from the azole class of antifungal drugs revealed
PSZ to be an equipotent inhibitor of the Hh signaling cascade. This finding guided the
design and development of next generation ITZ-PSZ hybrid analogues. However, the
task of preparing such chimeric molecules entailed a challenging multi-step synthetic
96

route. Aiming to simplify this synthetic route for the purpose of easy and efficient
medicinal chemistry investigations, necessary modifications to the existing synthetic
strategy were planned and successfully executed. Preliminary evaluation of two new
derivatives indicated that these hydroxylated side chain derivatives of ITZ maintain
potent Hh inhibitory activity in vitro. Taken together, an optimized methodology for rapid
synthesis of chirally defined hydroxylated side chain derivatives has led to the synthesis
of active Hh inhibitors and will prove to be advantageous for the future production of
related molecules.
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CHAPTER V: Future Directions in the Development of Small Molecule Inhibitors of
the Hh Pathway
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1. Contributions of VD3 project
The identification of aberrant Hh pathway signaling in a variety of human cancers
led to a surge in research projects that focused on the development of pathway inhibitors
as anti-cancer agents. Many of these initial drug discovery efforts focused on the
development of small molecules that target Smo, the most druggable target within the
pathway. Further, the FDA approval of GDC-0449 in early 2012 validated the clinical
efficacy of treating Hh-dependent cancers with a Smo antagonist. Our initial efforts
towards identifying improved Hh inhibitors began with studies based on VD3. To date,
the molecular target for VD3 in the context of Hh signaling has not been confirmed.
Therefore, in silico modeling or structure based drug designing was not feasible. Due to
this challenge, a chemical-biology approach was adopted and implemented in order to
successfully fulfill the goals of this project. Preliminary results suggesting that the
metabolic conversion of VD3 to its physiologically active form, calcitriol, activates VDR
signaling further led to the aim of repurposing the VD3 scaffold for selective Hh
modulation. The knowledge gathered from probing in vitro biological models with VD3
and its early analogues guided the design and discovery of improved next generation
derivatives. One of the most significant outcomes of these studies was a better
understanding of the structural requirements of VD3 for potent and selective Hh
inhibition (Figure 1). The CD-ring region of VD3 was determined to be the necessary
pharmacophore for Hh pathway inhibition. It was established that modifications of the Aring, seco B-ring and CD-ring side chain afforded greater selectivity for Hh modulation
thereby diminishing the detrimental effects of concomitant VDR activation. Taking into
account these key SAR findings, new VD3 based Hh antagonists were designed,
prepared and evaluated. Among these novel analogues, 95, 100 and 104 afforded
approximately four-fold improvement in Hh inhibitory activity while gaining greater than
1000-fold selectivity for Hh signaling over the VDR pathway.
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Figure 1. SAR of VD3 for potent and selective Hh pathway inhibition.
Another important contribution of this project was towards the optimization of in
vitro assay systems for expedited evaluation of Hh inhibitors. Developing reliable cell
based assays for monitoring endogenous Hh activity in cancer cell lines has proven to
be a significant challenge. According to the generally accepted notion, the tumor
microenvironment allowing cross talk with surrounding stromal cells is crucial for proper
Hh signaling in several forms of cancer. Therefore, accurate in vitro evaluation of
biological activities of potential Hh antagonists has been difficult owing to the lack of
paracrine mode of Hh signaling in cultured epithelial tumor cells. This shortcoming was
corroborated while working with human glioblastoma cell line U87MG to test A-ring
analogues of VD3. Thereafter, a qRT-PCR based assay using MEFs such as
C3H10T1/2 has been routinely employed for evaluating Hh inhibitors. Relatively higher
time and resources consumed in this assay, which arises from using low RNA yielding
MEF cells prompted us to search for suitable modifications to the assay protocol with the
intention of developing a higher throughput assay. Consequently, the assay was
optimized for a 96 or 24-well format to facilitate efficient screening of analogues with
reliability and reproducibility directly from the cell lysate using commercially available
Cells-to-CT kit (Life Technologies).
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Since esterase enzymes are abundant in in vitro and in vivo systems, ester
bonds are generally susceptible to metabolic cleavage under such environment. Thus, to
avert metabolic liabilities, ester linkages are typically avoided in a drug molecule except
when formulating a ‘pro-drug’. With these caveats in mind, we continued our exploration
of VD3 SAR employing this class of ester linked analogues for a few different reasons.
First, from a chemistry point of view, access to this group of analogues proved to be
quick and efficient allowing expedited synthesis and investigation of biological activities.
Next, based on distinct SAR trends it was established that observed activity is through
the intact ester-linked scaffold and not the resulting metabolites

113, 114

. Prior to

conducting in vivo studies, it will be essential to identify and incorporate a linker less
susceptible to metabolism while maintaining potent and selective Hh inhibition.
Functional moieties such as amide, carbamate or ureido which are generally ‘drug like’
linker groups are proposed for this purpose and are being prepared currently by other
researchers in the Hadden lab.
A comprehensive understanding of the subcellular components that interact with
VD3 is essential to developing VD3 analogues that exert their biological effects through
selective inhibition of Hh signaling. Ongoing studies designed to explore the cellular
mechanisms through which VD3 and its analogue 87 inhibit Hh signaling have focused
on the two cellular receptors previously associated with VD3 i.e. VDR and Smo.
Previously, tritiated analogue of VD3 was shown to selectively bind yeast cultures in
which expression of human Smo had been chemically induced

107

. In addition, this

binding was antagonized by the addition of Cyc. On the contrary, results from our
binding experiments suggest that neither VD3 nor 87 bind Smo in the Cyc binding
pocket; however, this data does not preclude binding to another regio n of Smo

114

.

Preliminary analysis of VDR-mediated Hh inhibition for VD3 and 87 suggested that VDR
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is required for the anti-Hh effects of VD3 but not for calcitriol or analogue 87. The
inability of VD3 to maintain Hh inhibition in the presence of VDR knockdown was
surprising for several reasons. First, similar studies performed in ASZ cells utilizing VDRspecific shRNA demonstrated that VDR knockdown did not affect the ability of VD3 to
down-regulate Gli1 mRNA expression 110. In addition, as demonstrated by our lab 108 and
others,

171

calcitriol inhibits Hh signaling in vitro and in vivo and these anti-Hh effects of

calcitriol were not abrogated in Vdr

−/−

fibroblasts

171

. More specifically, the ability of

calcitriol to inhibit Hh signaling in vitro has been localized to a step downstream of Ptch,
suggesting its effects may also be mediated via Smo. As our assays (C3H10T1/2) and
those previously reported (ASZ and fibroblasts) were performed in different cell lines, it
is clear that cellular context is essential for determining the mechanisms through which
VD3, calcitriol, and their analogues inhibit Hh signaling. Therefore, the development of
chemical probes that can definitively identify binding interactions will be necessary to
further our understanding of whether the anti-Hh effects of these sterols are mediated
via direct binding to Smo, or another, as yet unidentified, mechanism.
2. Contributions of ITZ project
Following the identification of ITZ as a potent Hh/Smo antagonist, several new
clinical trials have been initiated to assess the implications of repurposing this antifungal
drug for the treatment of Hh-driven cancers. Along with promising initial results from
these studies, an additional factor in favor of ITZ is its potent anti-Hh activity against the
known drug resistant forms of the signaling cascade

101, 117

. Irrespective of the final

consequences of current clinical trials, the ITZ scaffold is certainly a promising new drug
lead for the development of Hh inhibitors. Therefore, we examined possible design
strategies to develop ITZ based analogues for the inhibition of Hh signaling.
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During a comparative analysis of several azole antimycotic drugs, it was revealed
that PSZ exhibits potent Hh inhibition similar to ITZ. Hence, we prepared three
analogues that incorporate stereochemically defined hydroxylated side chains
reminiscent of the PSZ side chain to determine whether this enhanced Hh inhibitory
activity is mediated through the side arm region. Also, these analogues were designed
with the objective of enhancing water solubility of the otherwise poorly soluble ITZ
molecule. After several rounds of optimization with respect to previously reported
synthetic routes to either ITZ or PSZ, rapid access to this class of compounds was
accomplished.
With a protocol in place for the synthesis of chimeric ITZ-PSZ analogues, future
efforts can be directed towards preparing related analogues (Figure 2). This class of
analogues will provide SAR inferences regarding the effects of defined stereochemistry
of the side chain on Hh inhibition. Further, evaluation of potent analogues against drug
resistant forms of Smo will aid the identification of ideal candidates for advanced
development.

Figure 2. Additional side chain analogues of ITZ.
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3. Future outlook for the discovery and development of Hh pathway inhibitors
The recent identification of multiple mechanisms that can result in resistance to
Smo antagonists has led numerous researchers to target additional pathway
components. The general consensus has been that small molecules acting on targets
downstream of Smo, particularly at the level of the Gli transcription factors or on distinct
binding sites of Smo, hold more promise for resistant forms of Hh-dependent cancers.
Several research groups have identified pathway inhibitors that function through
inhibition of Gli function; however, the majority of these have only demonstrated modest
inhibitory activity in vitro and in-depth SAR, mechanism of action, and in vivo studies for
these compounds have not been reported. The last year has seen numerous structural
reports detailing several distinct small-molecule binding sites on Smo. Understanding
key molecular interactions between Smo antagonists and these binding sites may also
facilitate the design of small molecules with enhanced potency against resistant forms of
Smo. Meanwhile, a combination therapy approach has shown reasonable success in
inhibiting resistant forms of Hh signaling in human cancer. For instance coadministration with verapamil, an inhibitor of P-gp, restored the anti-Hh activity of IPI-926
in murine MB that had developed resistance due to IPI-926-induced overexpression of
P-gp

37

. In a separate study, co-administration of NVP-LDE225 with either the PI3K

inhibitor NVP-BKM120 or the dual PI3K-mTOR inhibitor NVP-BEZ235 significantly
delayed the development of resistance and enhanced MB tumor regression in animal
models

35

. Similarly, small molecule inhibitors of Aurora kinase or Polo -like kinase

demonstrated potent anti-tumor effects in vitro and in vivo in murine Ptch-/- MB both
alone and in combination with NVP-LDE225

172

. A related combination approach that

utilized two pathway inhibitors that act through diverse mechanisms has also proven
effective. Combined oral administration of ITZ and ATO in a subcutaneous allograft of
SmoD477G-driven MB demonstrated potent inhibition of both Hh signaling and tumor
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growth 101. While these combination studies have proven effective in a preclinical setting,
their advancement into clinical trials is necessary to definitively evaluate their ability to
inhibit resistant forms of Hh signaling in human cancer.
In addition to the issues associated with acquired resistance to Smo antagonists,
another limitation associated with the development of pathway inhibitors is related to
their general application across a wide-range of human cancers. While aberrant Hh
signaling has been implicated in various forms of human cancer, the scope of using Smo
antagonists as a monotherapy has proven limited. To date, only BCC and MB,
malignancies that are driven by specific mutations in Ptch, Smo, or Sufu have proven
amenable to this type of therapeutic intervention. IPI-926 was withdrawn from several
Phase II trials for failing to meet its endpoint against cance rs that are not generally
considered to be strictly Hh-dependent. In addition, the anti-cancer activity of pathway
inhibitors in vitro and in vivo in non-Hh-dependent cancers is often not correlative with
their anti-Hh effects

12, 108

. Again, there have been increasing reports in which a Smo

antagonist used in combination with another small molecule has demonstrated
promising preclinical or clinical activity. Specific examples include the clinical studies of
notch inhibitor RO4929097 combined with GDC-0449 in treating advanced or metastatic
sarcoma based on the fact that both of these signaling mechanisms are responsible for
sustaining sarcoma tumors

173

. Similarly, promising results have been reported in

combining GDC-0449 with gemcitabine and nab-paclitaxel against advanced pancreatic
cancer

174

.

As a whole, these results clearly highlight the anti-cancer potential of Hh pathway
inhibitors in Hh-dependent cancers, as well as the potential of combination regimens in
resistant or non-Hh-dependent cancer. Moreover, they also emphasize the need for
continued development to ensure there will be effective treatments for future patients

105

who experience detrimental side effects or are not responsive to the compounds
currently under development.
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